| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
PDS Biotechnology Corporation$0.77
-0.01 (-1.69%)
D 28Pipeline Score Richly Valued Pharma · Clinical
Market Cap
66.98 M
EPS
-0.67
P/E Ratio
-
Value Trade
810.99 K
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
3.46 M
Operating CF
-4.37 M
Total Assets
24.66 M
Total Liabilities
20.77 M
Equity
3.89 M
D/E Ratio
12,345
-14.29 %
Week
-11.11 %
1 Month
70.21 %
3 Month
60.56 %
6 Month
-83.45 %
5 Year
-99.48 %
All Time
Cash Data
Cash Position
21.66 M
Monthly Burn
1.46 M
Runway
13 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
305.58 K
52 Week Range
0.51 - 1.92
% held by Insiders
1.73 %
% held by Institutions
9.06 %
Enterprise Value
61.18 M
Total Shares
52.37 M
Short %
2.82 %
Float Shares
47.56 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for PDS Biotechnology Corporation
475Total events
6Upcoming
115Tier-1 (high impact)
2015 – 2027Coverage
Upcoming catalysts 6
Event history 469
Q2 2026
◆Enrollment CompleteCombination Treatment of PDS0101 and PembrolizumabTrial
Enrollment completion for VERSATILE-003
HPV16-positive recurrent/metastatic head and neck cancersource ↗
Q2 2026
◆Interim AnalysisCombination Treatment of PDS0101 and PembrolizumabTrial
PFS data readout (interim analysis) for VERSATILE-003
HPV16-positive recurrent/metastatic head and neck cancersource ↗
Q2 2026
◆Full ResultsPDS01ADCClinical Data
Preliminary data publication for PDS01ADC + docetaxel in metastatic castration resistant prostate cancer
Metastatic castration resistant prostate cancersource ↗
Q2 2026
◆Protocol AmendmentPDS01ADCTrial
Adoption of amended protocol for PDS01ADC + docetaxel trial
Metastatic castration resistant prostate cancersource ↗
Q2 2026
◆Full ResultsCombination Treatment of PDS0101 and PembrolizumabClinical Data
Phase 2 data publication for PDS0101 + CRT in cervical cancer
Cervical cancersource ↗
Mar 30, 2026
Mar 30, 2026
▲Protocol AmendmentCombination Treatment of PDS0101 and PembrolizumabTrial
Amended VERSATILE-003 protocol to incorporate PFS as interim primary endpoint
HPV16-positive recurrent and/or metastatic head and neck cancersource ↗
Mar 30, 2026
▲Oral PresentationPDS01ADCPresentation
Encouraging early results from NCI-led trial of PDS01ADC + docetaxel presented at AACR special conference on prostate cancer
metastatic castration-resistant prostate cancer (mCRPC)source ↗
Mar 30, 2026
▲Patent GrantedCombination Treatment of PDS0101 and PembrolizumabIP / Competition
New patents granted in U.S. and Japan for PDS0101
Mar 10, 2026
▲Full ResultsPDS01ADCClinical Data
Publication of interim Phase 2 data from Stage 1 of NCI-led mCRC trial in JCO Oncology Advances
metastatic colorectal cancer (mCRC)source ↗
Mar 2026
▲Full ResultsPDS01ADCClinical Data
Publication of positive clinical and immunological biomarker data from Stage 1 of NCI-led mCRC trial
metastatic colorectal cancersource ↗
Drug Pipeline Intelligence
D28
Pipeline Score $10M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.2x
rNPV / MCap Top 30%
Micro Cap (rank 639 of 912)
Percentile RankPDS Biotechnology Corporation faces pipeline headwinds (28/100), with $205M risk-adjusted pipeline value, led by Pembrolizumab and PDS0101 in Metastatic Head and Neck Cancer (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pembrolizumab and PDS0101 Small molecule | Metastatic Head and Neck Cancer | Phase 2 | NCT04260126 | 10% | $205M | COMPLETED | 95 | - | - | May 14, 2025 | - | Oct 1, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
PDS01ADC | unresectable metastatic colorectal cancer | Phase 2 | 2026-04-15 | objective response rate: 78%; two year survival rate with PDS01ADC: >80%; two year survival rate without PDS01ADC: ~35% Read More | PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial 78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial Read More | |
PDS01ADC | unresectable metastatic colorectal cancer | Phase 2 | 2026-04-15 | objective response rate: 78%; two year survival rate with PDS01ADC: >80%; two year survival rate without PDS01ADC: ~35% Read More | PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial 78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial Read More | |
PDS01ADC | unresectable metastatic colorectal cancer | Phase 2 | 2026-04-15 | objective response rate: 78%; two year survival rate with PDS01ADC: >80%; two year survival rate without PDS01ADC: ~35% Read More | PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial 78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PDSB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PDSB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PDSB▲ +20.9%on this news
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
PDS Biotechnology Corporation reported its financial results for Q1 2026, highlighting significant clinical advancements. The company is focused on resuming enrollment in its amended Phase 3 trial for PDS0101, while also noting successful enrollment in trials for PDS01ADC. Financially, PDSB showed a reduced net loss compared to the previous year, reflecting improved operational efficiency.
Read more →PDSBPDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results
PDS Biotechnology Corporation announced a conference call and webcast scheduled for May 13, 2026, to discuss its financial results for Q1 2026. The call will also include updates on clinical programs and corporate developments. The company is advancing its lead immunotherapy program, PDS0101, in pivotal trials for HPV16-positive head and neck cancers.
Read more →PDSBPrecision Designed Science for Cancer Patients NASDAQ: PDSB April 2026 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States S
PDS Biotechnology Corporation (PDSB) has released forward-looking statements regarding its development pipeline, including PDS0101, an innovative treatment targeting HPV-positive cancers. The company has reported successful disease control rates in recent clinical trials, especially for recurrent/metastatic head and neck squamous cell carcinoma. PDSB maintains collaborations with prominent cancer treatment institutions, emphasizing its strategic position in combating HPV-related cancers. However, the company also recognizes potential risks related to intellectual property, financing, and operational history as it navigates its future growth.
Read more →PDSB▲ +28.3%on this news
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial 78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial
PDS Biotechnology Corporation announced positive interim Phase 2 clinical trial results for its immunocytokine, PDS01ADC, in treating unresectable metastatic colorectal cancer. The trial, published in the Journal of Clinical Oncology, demonstrated a 78% objective response rate and an over 80% two-year survival rate among participants. The therapy combines PDS01ADC with hepatic artery infusion pump therapy, targeting tumors directly while minimizing systemic exposure. These findings indicate promising potential for PDS01ADC in a patient population where traditional therapies have been largely ineffective.
Read more →PDSBPDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement
PDS Biotechnology Corporation reported its financial results for 2025, highlighting progress in its clinical programs, particularly the VERSATILE-003 Phase 3 trial for PDS0101. The trial amendment aims to incorporate progression-free survival as an interim endpoint, potentially shortening its duration and reducing costs. Additionally, early results from the PDS01ADC trial showed promising outcomes in prostate cancer patients. The company also strengthened its intellectual property portfolio with new patents.
Read more →PDSB▲ +15.4%on this newsshared move
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results
PDS Biotechnology Corporation has announced a conference call and webcast scheduled for March 30, 2026, to discuss its financial results for the fourth quarter and year ended December 31, 2025. The call will also include updates on clinical programs and corporate developments. The company is actively engaged in pivotal trials for its lead immunotherapy program targeting advanced HPV16-positive cancers.
Read more →PDSBPrecision Designed Science for Cancer Patients NASDAQ: PDSB February 2026 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United State
PDS Biotechnology Corporation announced forward-looking statements regarding its lead program, PDS0101 (Versamune HPV), aimed at treating HPV16-positive head and neck cancers. The company is preparing for a pivotal Phase 3 trial under the FDA's accelerated approval pathway, citing positive preliminary results. However, PDS Biotech faces challenges related to financing and uncertainties regarding the timing and outcomes of its clinical trials. Despite a promising innovative treatment platform, operational risks remain a significant concern for the future success of the company.
Read more →PDSBPDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval
PDS Biotechnology Corporation has announced an amendment to its Phase 3 VERSATILE-003 trial protocol, incorporating progression-free survival (PFS) as an interim primary endpoint. This change aims to support a potential accelerated approval pathway for PDS0101 in treating HPV16-positive recurrent and/or metastatic head and neck cancer. The trial's primary endpoint for full approval remains median overall survival (mOS).
Read more →PDSBPDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
PDS Biotech announced preliminary results from a Phase 2 study of PDS01ADC in patients with metastatic castration-resistant prostate cancer, showing a median progression-free survival of 9.6 months. The study, led by the NCI, also reported a median PSA decline of 40%, indicating potential benefits of the treatment. These findings were presented at the AACR conference.
Read more →PDSBPDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
PDS Biotechnology Corporation announced the issuance of a Notice of Allowance for a new U.S. patent covering its lead asset, PDS0101. This patent enhances the company's intellectual property estate and, combined with anticipated biologics exclusivity, provides over 20 years of market protection. The company is advancing PDS0101 through the Phase 3 VERSATILE-003 clinical trial for HPV16-positive head and neck cancers.
Read more →PDSB▲ +7.7%on this news
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint
PDS Biotech has submitted an amended protocol to the FDA for its Phase 3 VERSATILE-003 trial, changing the primary endpoint to Progression Free Survival (PFS). This change aims to facilitate an earlier evaluation and potentially accelerate the approval of PDS0101 for HPV16-positive cancers. The amendment follows positive results from the previous trial and retains median overall survival as a requirement for full approval.
Read more →PDSB▲ +18%on this news
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan New Patent Grants Broad Composition Claims for PDS0101 Previously Granted Patent Protections and Anticipated Market Exclusivity Provide Protecti
PDS Biotech has announced that the Japan Patent Office granted a new patent for PDS0101, enhancing its composition of matter claims and methods of use. This patent adds to the company's existing protections in multiple countries, leading to robust intellectual property coverage and anticipated market exclusivity into the 2040s. The development comes as a response to the rising incidence of HPV16-related cancers and underpins the clinical research underway for PDS0101 combined with pembrolizumab. The CEO highlighted the importance of this patent in supporting the company's growth and innovative immunotherapy pipeline.
Read more →PDSB▲ +10.9%on this news
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)
PDS Biotechnology Corporation has scheduled a Type C Meeting with the FDA to discuss an accelerated approval pathway for its treatment PDS0101 in HPV16-positive recurrent and/or metastatic Head and Neck Cancer. This follows positive results from the VERSATILE-002 trial, which demonstrated promising overall survival and progression-free survival. The proposed amendment to the VERSATILE-003 trial aims to adjust the primary endpoint to facilitate earlier evaluation for potential approval.
Read more →PDSB▼ -12.3%on this news
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update
PDS Biotechnology Corporation reported its third quarter 2025 financial results, highlighting the completion of the VERSATILE-002 Phase 2 trial. The company plans to seek an expedited approval pathway for its ongoing VERSATILE-003 Phase 3 trial based on positive data. Financially, PDSB reduced its net loss compared to the previous year, although its cash reserves have significantly declined.
Read more →PDSB▼ -7%on this news· ran to -26% by day 3shared move
PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering
PDS Biotechnology Corporation has announced a registered direct offering to raise up to $11.1 million by selling 5.8 million shares of common stock at $0.91 each. The proceeds will primarily fund the VERSATILE-003 Phase 3 clinical trial and other corporate expenses. The offering is expected to close on or about November 12, 2025.
Read more →PDSB▲ +7%on this newsshared move
PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025
PDS Biotechnology announced promising clinical and translational data for its immunotherapies PDS0101 and PDS01ADC at the SITC 2025 Annual Meeting. The findings highlight immune mechanisms and biomarkers that correlate with strong clinical activity, reinforcing the scientific basis for these therapies. The company is advancing these therapies toward commercialization for patients with challenging cancers.
Read more →PDSBPDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results
PDS Biotechnology Corporation will host a conference call on November 13, 2025, to report its financial results for Q3 2025 and provide updates on its clinical programs. The call will be accessible via dial-in and webcast, with an archive available for six months. The company is focused on immunotherapy for cancer treatment.
Read more →PDSB▼ -5.9%on this news
New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting
PDS Biotechnology Corporation announced that new clinical data on its investigational cancer therapies PDS0101 and PDS01ADC will be presented at the 2025 Society for Immunotherapy of Cancer Annual Meeting. The National Cancer Institute will showcase three abstracts that detail emerging findings from these therapies, emphasizing their potential to enhance immune responses against cancer. This presentation reflects PDS's commitment to advancing novel immunotherapy candidates.
Read more →PDSB▲ +8.3%on this newsshared move
PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer
PDS Biotech is seeking an expedited FDA approval pathway for PDS0101 in HPV16-positive head and neck cancer, following promising results from the VERSATILE-002 trial. The company plans to amend the VERSATILE-003 trial to include progression-free survival as a primary endpoint, potentially allowing for accelerated approval. The trial is currently paused while awaiting FDA feedback.
Read more →PDSBPDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1–19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population
PDS Biotechnology announced significant findings from its VERSATILE-002 trial, showing that its combination therapy of PDS0101 and Keytruda resulted in a median overall survival of 29.5 months for patients with low PD-L1 expression. This represents a substantial improvement over the standard treatments, which had median survivals of 10.8 and 12.3 months. The results suggest a promising alternative for patients who typically respond poorly to existing therapies.
Read more →PDSBPDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
PDS Biotechnology Corporation will participate in the 27th Annual H.C. Wainwright Global Investment Conference from September 8-10, 2025. CEO Frank Bedu-Addo and CFO Lars Boesgaard will hold one-on-one meetings with investors. The company is focused on immunotherapy for cancers, particularly its lead program targeting HPV16-positive head and neck cancers.
Read more →PDSB▲ +9.2%on this news
PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer
PDS Biotechnology announced final topline survival data from the VERSATILE-002 Phase 2 trial, showing a median overall survival of 39.3 months for patients treated with PDS0101 and pembrolizumab. This result outperforms the standard of care, which has a median survival of 17.9 months. The company is optimistic about the implications for HPV16-positive head and neck cancer patients and plans to publish full data later this year.
Read more →PDSB▲ +9.2%on this newsshared move
Precision Designed Science for Cancer Patients NASDAQ: PDSB August 2025 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States
PDS Biotechnology Corporation reported forward-looking statements concerning its product candidates, particularly PDS0101 for HPV16-positive head and neck cancers. The company highlights successful Phase 2 clinical trial results, indicating a median overall survival of 39.3 months, outperforming current standard care. However, it acknowledges several risks, including dependency on fundraising, operational challenges, and the need for further studies to compare its treatments with existing therapies. The company’s partnerships with major cancer institutions are aimed at validating its clinical approach, particularly in addressing significant unmet needs in HPV16-related cancers.
Read more →PDSB▼ -5.7%on this news
PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update Multiple Abstracts Presented at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast to
PDS Biotech has reported its financial results for the second quarter of 2025, showing a net loss of $9.4 million. The company noted progress in its pivotal VERSATILE-003 clinical trial for PDS0101 in HPV-positive head and neck cancers. Additionally, a presentation at the American Society of Clinical Oncology Annual Meeting shared encouraging data from the VERSATILE-002 trial. However, the company's cash balance has seen a significant decrease compared to the previous year, highlighting potential liquidity challenges.
Read more →PDSBPDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results Metastatic Colorectal Cancer Cohort in NCI-Led Multi-Cohort
PDS Biotechnology Corporation has announced that its Phase 2 clinical trial for PDS01ADC, focusing on metastatic colorectal cancer, has progressed to Stage 2 following positive results from Stage 1. The trial, led by the National Cancer Institute, has indicated a sufficient response rate to allow continued participant enrollment. PDS01ADC is designed as an antibody drug conjugate that targets tumor necrosis areas, potentially offering new treatment options for a challenging cancer type. Patient recruitment for this cohort is expected to be completed by the end of 2025.
Read more →PDSB▼ -5.6%on this news· ran to -17% by day 3
Addressing the Growing Incidence of HPV16-Related Cancers NASDAQ: PDSB June 2025 Precision Designed Science For Immunotherapy Forward-Looking Statements This communication contains forward-looking statements (including w
PDS Biotechnology Corporation is increasing its focus on addressing the growing incidence of HPV16-related cancers, particularly HPV16-positive head and neck squamous cell carcinoma (HNSCC). The company highlights its lead immunotherapy, Versamune HPV, which has shown promising survival results in early studies and has received FDA Fast Track designation. The potential market for this indication is significant, with projections indicating a $4-6 billion opportunity in the US and EU. However, the company faces challenges such as financial dependency and uncertain future results from ongoing trials.
Read more →PDSBPDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Med
PDS Biotechnology Corporation announced promising results from the VERSATILE-002 trial at the 2025 ASCO Annual Meeting, focusing on its lead immunotherapy, Versamune HPV. The trial revealed a median overall survival of 30.0 months for patients with recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC) over an extensive follow-up period. As HPV16-positive cases are the fastest-growing type of HNSCC in the US, the positive findings signal a potential breakthrough for targeted treatments in this population. Researchers noted the importance of developing companion diagnostics to better identify patients suitable for this therapy.
Read more →PDSBPDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Phase 2: Ver
PDS Biotechnology Corporation has announced promising extended follow-up data for its VERSATILE-002 study, showing significant overall survival rates for patients receiving their Versamune HPV treatment in combination with pembrolizumab. The median overall survival for patients with a CPS score of 20 was reported at 39.3 months and 30 months for those with a CPS score of 1. The company is also conducting VERSATILE-003, a Phase 3 study currently enrolling patients, aimed at further evaluating the treatment's efficacy. These findings are set to be presented at the 2025 ASCO Annual Meeting, contributing to the ongoing discourse in head and neck cancer treatment.
Read more →PDSBPDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update VERSATILE-003 Phase 3 Site Initiations Underway Multiple Abstracts Selected for Presentation at the 2025 Americ
PDS Biotech has reported its financial results for the first quarter of 2025 and provided updates on its clinical programs. The initiation of the VERSATILE-003 Phase 3 trial evaluating the Versamune HPV therapy for recurrent/metastatic HPV16-positive head and neck squamous carcinoma has commenced, with site activations underway, including key sites at Mayo Clinic. Financially, the company reported a reduced net loss compared to the previous year, alongside a decrease in operating expenses. PDS Biotech's cash balance as of March 31, 2025, stands at $40 million.
Read more →PDSB▲ +5.2%on this news
PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025 Annual Meeting Infectimune studies funded by and performed by investigators at the National Institute of All
PDS Biotech has provided updates on its preclinical data for the Infectimune-based universal influenza vaccine during the IMMUNOLOGY2025 Annual Meeting. The presentations highlighted significant improvements in immune response, particularly in targeting influenza-specific CD4 T cells, which exhibited superior protective capabilities. With increasing interest in universal vaccines, PDS Biotech's approach could represent a significant advancement in influenza vaccine development while maintaining a commitment to ongoing immunotherapy programs. The findings are poised to contribute to broader discussions on vaccine technology in high-risk populations.
Read more →PDSBPDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune HPV in HPV16-Positive Head and Neck Cancer Conference call an
PDS Biotechnology Corporation has announced its full-year financial results for 2024 and provided an update on its clinical programs, notably the initiation of the VERSATILE-003 Phase 3 clinical trial for Versamune HPV targeting HPV16-positive head and neck cancer. CEO Frank Bedu-Addo highlighted the urgency of developing targeted therapies for this cancer type, underlining the promising clinical responses from prior studies. Additionally, the company reported a reduced net loss, reflecting improved operational efficiency. This trial marks a pivotal step for PDS Biotech in advancing its innovative immunotherapy treatments.
Read more →PDSB▲ +5.9%on this news· ran to +17% by day 3
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer Phase 1/2 trial evaluating the proprietary combination to be run under CRADA wit
PDS Biotech has announced that the FDA has cleared its IND application for a combination therapy using Versamune MUC1 and PDS01ADC to treat metastatic colorectal cancer (mCRC). This Phase 1/2 clinical trial will be conducted in collaboration with the National Cancer Institute under a CRADA. The combination aims to address the unmet needs of patients with MUC1-positive unresectable mCRC who have failed prior therapies. The company holds a patent covering methods of utilizing this combination to enhance anti-tumor immune responses.
Read more →PDSB▼ -8.2%on this news
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune HPV in HPV16-Positive Head and Neck Cancer First-ever HPV16-positive head and neck cancer Phase 3 clinical trial PRINCETON, N.J.
PDS Biotechnology has announced the initiation of the VERSATILE-003 Phase 3 clinical trial for Versamune HPV in HPV16-positive head and neck cancer, marking the first trial of its kind. The trial aims to evaluate the safety and efficacy of its immunotherapy in combination with pembrolizumab, enrolling approximately 350 patients. This advancement follows positive results from the VERSATILE-002 study, and the company expresses confidence in improving treatment outcomes for patients suffering from this cancer type.
Read more →PDSB▼ -11.7%on this news
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules $11 Million Upfront with up to an Additional $11 Million of Aggregate Gross Proceeds Upon the Cash Exercise in Fu
PDS Biotechnology Corporation announced a registered direct offering aiming for up to $22 million in gross proceeds. The offering will include an upfront amount of $11 million, with potential for an additional $11 million through warrant exercises. The company plans to use the net proceeds primarily for research and development activities. The offering is expected to close on or about February 28, 2025, pending customary closing conditions.
Read more →PDSB▲ +22.2%on this newsshared move
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology Median Overall Survival (mOS) of 42.4 months
PDS Biotech has announced significant advancements in its clinical trials for recurrent/metastatic HPV-associated cancers, with results published in JAMA Oncology. The triple combination therapy of Versamune HPV, PDS01ADC, and a PD-L1 immune checkpoint inhibitor demonstrated promising median overall survival rates and a high objective response rate in patients. These results suggest a transformative potential for the treatment of HPV-associated cancers, prompting the company to initiate a Phase 3 trial focused on HPV16-positive head and neck cancer. The findings position PDS Biotech as a key player in the immunotherapy landscape for these cancers.
Read more →PDSB▼ -5.2%on this newsshared move
PDS Biotech Announces Circulating Tumor DNA Results for Versamune HPV in IMMUNOCERV Trial Published in Clinical Cancer Research Data confirms Versamune HPV has potential as a broadly effective treatment of HPV16-associat
PDS Biotech announced positive results from the IMMUNOCERV trial of Versamune HPV, demonstrating its effectiveness against HPV16-associated cancers. The trial revealed that 100% of patients treated with a combination of Versamune HPV and chemoradiation showed no detectable HPV16 ctDNA within 3-4 months. This successful outcome correlates with significantly improved recurrence-free survival rates, leading to plans for a Phase 3 trial in HPV16-positive head and neck squamous cell carcinoma starting in Q1 2025. The findings have been published in Clinical Cancer Research, emphasizing Versamune HPV's potential as a transformative treatment option.
Read more →PDSBPDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma FDA-cleared amended trial design; First sit
PDS Biotech has reaffirmed its guidance to begin the VERSATILE-003 Phase 3 clinical trial for its immunotherapy product targeting HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma in the first quarter of 2025. The trial's design has received FDA clearance and the company has secured Fast Track designation for its combination therapy. This study is particularly significant as it will utilize a newly validated companion diagnostic to screen patients, further positioning HPV16-positive HNSCC as a notable area of focus in oncology.
Read more →PDSB▼ -18.3%on this news
PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results Conference call and webcast today at 8:30 a.m. Eastern Time PRINCETON, N.J.
PDS Biotechnology Corporation provided an update on its clinical programs and reported financial results for the third quarter of 2024. The company is progressing in its VERSATILE-003 Phase 3 trial concerning HPV-related cancers, with modifications made to the trial design aimed at reducing costs and time to results. They anticipate FDA clearance by mid-December 2024 to activate trial sites in 2025. Additionally, promising data from the IMMUNOCERV Phase 2 trial were presented, demonstrating favorable clinical activity and safety. Despite the overall positive outlook, the company reported a net loss for the quarter, which has raised concerns regarding its financial health.
Read more →PDSB▲ +12.6%on this news
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune HPV and Chemoradiation 100% 36-month overall survival (OS) and progression-free survival (
PDS Biotechnology Corporation announced encouraging results from its IMMUNOCERV Phase 2 clinical trial evaluating Versamune HPV for locally advanced cervical cancer. The study reported a 36-month overall survival rate of 84.4% alongside a complete metabolic response in 88% of participants. These findings were presented at the ASTRO Annual Meeting 2024 and indicate a promising future for further investigation into this immunotherapy. The company plans to advance its clinical program for Versamune HPV in treating HPV-positive cervical cancers.
Read more →PDSBPDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024 Median Overall Survival remains at 30 months; Objective Response Rate of 36% and Disease Control Rate of 77% 11/53 (2
PDS Biotechnology Corporation reported updated results from its VERSATILE-002 Phase 2 trial of Versamune HPV combined with KEYTRUDA, presenting at the ESMO 2024 Congress. The trial, which focused on HPV16-positive head and neck cancer patients, revealed a median overall survival of 30 months, a 36% objective response rate, and a disease control rate of 77%. The company plans to initiate a Phase 3 clinical trial, VERSATILE-003, later this year to further evaluate this promising treatment combination.
Read more →PDSB▼ -5.1%on this news
Transforming How the Immune System Targets and Fights Cancer to Promote Survival NASDAQ: PDSB September 2024 Precision Designed Science For Immunotherapy Forward-Looking Statements This communication contains forward-loo
PDS Biotechnology Corporation is advancing its immunotherapy efforts with the Versamune platform, particularly targeting HPV16-positive recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). The company reports encouraging Phase 2 trial outcomes, such as a 30-month median overall survival and a 77% disease control rate. The FDA has granted Fast Track designation for the Versamune HPV program alongside plans to initiate a Phase 3 study in late 2024. While there are confident projections regarding market potential, PDSB faces risks related to funding and the execution of clinical trials.
Read more →PDSBPDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results PRINCETON, N.J.
PDS Biotech has issued a business update alongside its second-quarter 2024 financial results, highlighting a strategic alignment with the FDA for a Phase 3 clinical trial of Versamune HPV combined with pembrolizumab. The company has noted promising data from the previously conducted VERSATILE-002 trial, which is informing the updated design of the upcoming trial. Financially, PDS Biotech demonstrated improved performance with a reduced net loss and lower operating expenses compared to the previous year. The expectation is set for more data presentation at the forthcoming ESMO 2024 Congress.
Read more →PDSBPDS Biotech Announces Abstract Accepted for Oral Presentation at 2024 ASTRO Annual Meeting PRINCETON, N.J.
PDS Biotechnology Corporation announced that updated data from its IMMUNOCERV Phase 2 clinical trial will be presented at the 2024 ASTRO Annual Meeting. The trial examines the use of Versamune HPV combined with chemoradiation for the treatment of locally advanced cervical cancer. The oral presentation is scheduled for October 1, 2024, in Washington, DC. The company also plans to initiate a pivotal clinical trial in 2024 focusing on advanced HPV16-positive head and neck squamous cell cancers.
Read more →PDSBPDS Biotech to Announce Second Quarter Financial Results on
PDS Biotechnology Corporation has announced the upcoming release of its financial results for the second quarter of 2024, which will take place on August 13, 2024. In addition to the financial report, the company will provide a business update. PDS Biotech is dedicated to advancing its immunotherapy programs, including a pivotal clinical trial aimed at treating advanced HPV16-positive head and neck squamous cell cancers, highlighting significant developments in its drug pipeline.
Read more →PDSBPDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024 PRINCETON, N.J.
PDS Biotechnology Corporation announced that an abstract showcasing updated data from the VERSATILE-002 trial has been accepted for presentation at the ESMO Congress 2024. The trial evaluates the first-line treatment of the Versamune HPV therapeutic vaccine in combination with Pembrolizumab for patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma. The congress will take place in Barcelona from September 13-17, 2024, with notable presentations by leading experts in the field.
Read more →PDSB▼ -9.3%on this newsshared move
PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern
PDS Biotech has aligned with the FDA regarding its Phase 3 VERSATILE-003 trial for treating HPV16-positive head and neck cancer using its investigational immunotherapy Versamune HPV. The trial is set to begin in Q4 2024, focusing on double and triple combination therapies. The FDA's support and the promising results from earlier trials provide an optimistic outlook for the potential effectiveness of this treatment. A conference call discussing the trial's details is scheduled for today at 8:00 a.m. ET.
Read more →PDSB▲ +6.2%on this news
PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overa
PDS Biotech has provided an update on its ongoing VERSATILE-002 Phase 2 clinical trial for HPV16-positive head and neck squamous cell cancer. The median overall survival remains stable at 30 months after additional follow-up with patients. The company plans to move towards a pivotal Phase 3 trial to assess the efficacy of its treatment, which combines Versamune with KEYTRUDA. While the preliminary data suggests promising potential, there are concerns regarding the conventional low survival rates associated with current therapies.
Read more →PDSBPDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results Provided Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune HPV in Combination with KEYTRUDA in Recurrent
PDS Biotech has reported positive updates regarding its Phase 2 VERSATILE-002 clinical trial, showing promising data for its Versamune HPV in combination with KEYTRUDA for treating recurrent or metastatic head and neck cancer. The company also noted a substantial financial update for Q1 2024, with a net loss of approximately $10.6 million, attributed primarily to increased operational costs. While the financial results show increased expenses, the company maintains a solid cash position of approximately $66.6 million, which supports its future clinical trial initiatives planned for this year.
Read more →PDSBPDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer 30 month median overall survival (OS); median OS independent of patien
PDS Biotech's VERSATILE-002 Phase 2 clinical trial demonstrated positive outcomes in patients with first-line recurrent or metastatic HPV16-positive head and neck cancer, achieving a 30-month median overall survival rate. The trial showed an objective response rate of 34% in patients with CPS 1 and 48% in CPS 20. The company plans to advance to a Phase 3 registrational trial in 2024 to further evaluate the efficacy of its dual-acting immunotherapy approach.
Read more →PDSB▲ +6.5%on this newsshared move
Transforming How the Immune System Targets and Fights Cancer to Promote Survival 2024 PDS Biotechnology. All Rights Reserved. NASDAQ: PDSB May 2024 Precision Designed Science For Immunotherapy Forward-Looking Statement T
PDS Biotechnology Corporation is focusing on transforming cancer treatment through its innovative Versamune platform, particularly targeting head and neck cancers. The company has plans to initiate a pivotal trial for its investigational product candidates PDS01ADC and PDS0101 in 2024. Positive survival data and a favorable safety profile bolster the prospects of its therapies, despite challenges related to financing and intellectual property protection. The dual action mechanism of PDS01ADC aims to enhance the immune response against tumors, which sets it apart in the landscape of cancer immunotherapy.
Read more →PDSBPDS Biotech Appoints Stephan Toutain as Chief Operating Officer Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J.
PDS Biotechnology Corporation has appointed Stephan Toutain as Chief Operating Officer effective May 1, 2024. Toutain brings over 30 years of experience in the pharmaceutical industry, particularly in oncology and drug commercialization. His role is expected to enhance the company's late-stage clinical strategies and the development of its innovative immunotherapy products. The company also granted him a stock option to purchase 200,000 shares as part of his inducement package, aligning his interests with the company's future success.
Read more →PDSB▼ -14.1%on this news
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results Unique mechanism of action of the combination of PDS01ADC and Versamune results in 3-year survival of 75% and 75% overall respon
PDS Biotech has announced an update to its clinical strategy, prioritizing a triple combination therapy of PDS01ADC, Versamune HPV, and KEYTRUDA for advanced head and neck cancer. The combination therapy demonstrated a 75% overall response rate in trials, leading to a strategic pivot from other studies. The firm also discussed its financial results, showing a net loss of approximately $42.9 million for the year ended 2023, which reflects increased operating expenses. The company aims to address the unmet medical needs in recurrent metastatic HPV-positive head and neck cancers with this promising approach.
Read more →PDSBPDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune Preclinical research published in Vaccines demonstrates Infectimune significantly improved quantity
PDS Biotech announced the publication of preclinical research demonstrating that its Infectimune platform significantly improves the quantity and quality of CD4 T cells in combination with the Flublok vaccine. Additionally, the company received a U.S. patent for its vaccine compositions utilizing Infectimune. These developments highlight the potential for Infectimune to offer broader and more effective protection against influenza and its variants.
Read more →PDSBPDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer Board-certified oncologist and hematologist brings over 30 years of medical affairs, clinical o
PDS Biotech has announced the retirement of Chief Medical Officer Lauren V. Wood, M.D., and the appointment of Kirk V. Shepard, M.D., effective January 22, 2024. Dr. Shepard, a board-certified oncologist and hematologist with over 30 years of experience, will take over the role and lead PDS Biotech's transition from clinical research to commercialization efforts for their cancer immunotherapy candidates. The company expressed gratitude for Dr. Wood’s contributions during her tenure. Additionally, Shepard has been granted stock options as part of his employment agreement.
Read more →PDSBDeveloping Transformational Immunotherapies for Cancer NASDAQ: PDSB December 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the Unit
PDS Biotechnology Corporation is advancing its immunotherapy candidate PDS0101 to a Phase 3 registrational trial in Q1 2024, targeting HPV16-positive head and neck squamous cell cancer (HNSCC). The company has received Fast Track Designation from regulatory authorities, supporting the urgency of this treatment option. Financially, PDSB is positioned well with adequate funding into Q3 2024. The management team brings extensive experience in drug development and commercialization, bolstering confidence in their product pipeline.
Read more →PDSB▼ -9.7%on this news
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer PRINCETON, N.J., November 28 , 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage immun
PDS Biotechnology Corporation has announced the appointment of Lars Boesgaard as its new Chief Financial Officer, effective December 4, 2023. Boesgaard succeeds Matthew Hill, who resigned to pursue other professional endeavors. With over 25 years in healthcare finance, Boesgaard brings significant expertise aimed at driving growth and operational maturity for PDS Biotech. The company continues to advance its targeted cancer immunotherapy pipeline, including plans for pivotal clinical trials in 2024.
Read more →PDSB▲ +18.6%on this news
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update Announced 75% of ICI-naive patients alive at 36 months in the NCI-led triple Phase 2 combination trial for advanced HPV16-positive can
PDS Biotechnology Corporation reported its financial results for the third quarter of 2023, highlighting positive outcomes from a National Cancer Institute-led Phase 2 trial. The trial demonstrated a 75% survival rate among ICI-naive patients at 36 months and a favorable safety profile. Despite these positive developments, the company reported an increased net loss compared to the same period last year, largely due to rising research and administrative costs. PDS Biotech remains optimistic about advancing its pipeline, including upcoming trials in 2024.
Read more →PDSB▲ +5.4%on this news· ran to +34% by day 3shared move
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101 Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which shows 75% Survival of ICI Na ve Patients at 36
PDS Biotech has released updated survival data from a Phase 2 clinical trial of its investigational therapy PDS0101 in combination with PDS0301 and an immune checkpoint inhibitor for advanced HPV16-positive cancer patients. The trial demonstrated a 75% survival rate at 36 months for patients who had not previously received an immune checkpoint inhibitor, while 72% of the ICI resistant group survived at 12 months. These results are significantly higher than typical survival rates associated with standard care. The company plans to advance towards a registrational trial based on this positive data.
Read more →PDSBPDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO Combination of PDS0101 and KEYTRUDA appears to lead to changes towards a TH1 predominant
PDS Biotech has announced preliminary results from a biomarker study on PDS0101 in combination with KEYTRUDA for treating HPV-positive head and neck cancer. Presented at the ESMO Congress 2023, the data shows potential positive changes in immune responses, particularly a shift towards a TH1 predominant profile among patients. The study involved 18 patients, with immune profiles assessed at multiple time points during treatment, revealing promising immunological activity with the combination therapy. Further investigations are planned in the ongoing VERSATILE-003 Phase 3 study.
Read more →PDSBPDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer First study of pati
PDS Biotech announced positive interim data from its Phase 1/2 clinical trial evaluating PDS0301, an antibody drug conjugate, in combination with docetaxel for treating metastatic prostate cancer. The data, presented at the Cytokines 2023 conference, highlights increases in immune responses without significant toxicity. Eighteen patients were evaluated, showing that the treatment was well-tolerated, particularly at a dose of 12.0 mcg/kg. The results may indicate a promising avenue for improving treatment for advanced prostate cancers.
Read more →PDSB▼ -14.5%on this news
Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB October 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the Unite
PDS Biotechnology Corporation announced the progression of PDS0101, which is set to enter Phase 3 registrational trials in 2023, targeting recurrent or metastatic HPV16-positive head and neck squamous cell cancer. The company holds an adequate cash runway for about 12 months, aimed at supporting ongoing and future clinical trials. Despite the promising developments in their immunotherapy platforms, the company acknowledges substantial risks due to potential uncertainties in achieving their future goals and necessary funding.
Read more →PDSB▼ -14.5%on this news
PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Na ve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA (pembrolizumab) Interim VERSATILE-002 data
PDS Biotech announced interim results from its VERSATILE-002 Phase 2 clinical trial, which demonstrated a 24-month survival rate of 74% for patients with unresectable HPV16-positive head and neck cancer treated with PDS0101 in combination with KEYTRUDA. Despite positive results in the ICI naive cohort, the company will not proceed with further development for the ICI refractory patient group. Planned advancements include initiating a Phase 3 trial, VERSATILE-003, to further assess the efficacy and safety of PDS0101 combined with KEYTRUDA. This trial emphasizes the importance of overall survival as its primary endpoint.
Read more →PDSB▼ -14.5%on this news
PDS0101 in HPV16+ Head and Neck Cancer KOL Roundtable NASDAQ: PDSB
PDS Biotech's roundtable discussion highlighted the ongoing developments of PDS0101, focusing on its potential in treating HPV16+ head and neck cancer. Experts from various oncology institutions presented findings and anticipated the initiation of further clinical trials. The conversation also addressed current treatment approaches and the unmet needs within the HPV16+ cancer landscape. The company's success will heavily depend on upcoming trials and the management of funding and operational challenges.
Read more →PDSB▼ -6.9%on this news· ran to -20% by day 1shared move
PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA) Study evaluated levels of circulating cell-free HPV DNA (cfDNA) in patients with locally
PDS Biotechnology announced promising results from the IMMUNOCERV Phase 2 trial, where lead candidate PDS0101 combined with standard chemoradiotherapy showed a rapid decline in circulating HPV DNA in cervical cancer patients. The trial results were presented at the ASTRO 2023 Annual Meeting, highlighting that PDS0101 led to more than 60% tumor shrinkage in high-risk patients. This data suggests PDS0101 could significantly impact treatment responses for HPV-positive cancers, with further evaluations planned to understand its efficacy and safety better.
Read more →PDSBPDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies PDS0202 (Infectimune + COBRA influenza antigens) vaccination also prevented illness/weight loss Vaccine pro
PDS Biotech has announced positive preclinical results for its investigational universal influenza vaccine PDS0202, which showed active neutralization of multiple influenza strains and protection against H1N1 in ferrets. This latest data was presented at the ESWI Conference, highlighting the potential of the vaccine to generate robust immune responses. The results align with prior findings and raise optimism for advancing the candidate into clinical trials aimed at creating broader protection against seasonal and pandemic influenza strains.
Read more →PDSBDeveloping Transformational Immunotherapies for Cancer NASDAQ: PDSB September 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the Uni
PDS Biotechnology Corporation is advancing its transformational immunotherapies for cancer, specifically aiming to initiate a Phase 3 registrational trial for its product candidate PDS0101 targeting recurrent HPV16-positive head and neck squamous cell carcinoma in 2023. The company boasts a strong cash position of $60.6 million, ensuring a runway for the next year. However, it faces various risks, including the dependence on future financing and a limited operating history, which may complicate evaluations of its business prospects. The management team brings extensive experience in pharmaceutical development, potentially positioning the company for market leadership.
Read more →PDSBPDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference PRINCETON, N.J.
PDS Biotechnology Corporation announced that it will present preclinical data for its universal influenza vaccine, PDS0202, at the 9th ESWI Conference in Valencia, Spain. The data suggests that vaccinated ferrets produce sero-protective antibody responses against notable influenza strains (H1N1 and H3N2). The oral presentation is scheduled for September 19, 2023, and aims to advance discussions on future vaccination strategies against influenza.
Read more →PDSBDeveloping Transformational Immunotherapies for Cancer NASDAQ: PDSB August 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United
PDS Biotechnology Corporation is advancing its lead product candidate, PDS0101, into a Phase 3 registrational trial in 2023, targeting recurrent or metastatic HPV16-positive head and neck squamous cell cancer. The company reported a cash position of $60.6 million as of June 30, 2023, which is expected to support operations for a year. Notable data from previous Phase 2 studies indicate PDS0101 could address significant unmet medical needs in its target market. The company emphasizes its innovative T cell activating platforms aimed at enhancing the effectiveness of cancer immunotherapies.
Read more →PDSB▲ +6%on this newsshared move
PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting Study evaluates the effect of c
PDS Biotechnology Corporation announced that data from its IMMUNOCERV Phase 2 trial evaluating PDS0101 in combination with chemoradiotherapy for cervical cancer will be featured in an oral presentation at the upcoming ASTRO 2023 Annual Meeting. The trial focuses on assessing the relationship between circulating HPV viral DNA levels and treatment outcomes in patients with advanced cervical cancer. Dr. Aaron Seo from The University of Texas MD Anderson Cancer Center will present the findings, which aim to provide insights into how PDS0101 may influence clinical outcomes.
Read more →PDSB▲ +9.9%on this news· ran to +21% by day 1shared move
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial VERSATILE-003 will evaluate PDS0101 in combination with KEYTRUDA in recurrent or metastatic HPV16-positive head and neck cancer
PDS Biotechnology Corporation has announced the submission of a Phase 3 protocol to the FDA for the VERSATILE-003 trial. This trial will evaluate PDS0101 in combination with KEYTRUDA for patients with recurrent or metastatic HPV16-positive head and neck cancer. The study aims to confirm positive interim data from the Phase 2 trial and is expected to commence in Q4 2023, involving 90-100 clinical sites globally.
Read more →PDSB▲ +9.9%on this news· ran to +21% by day 1shared move
PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update Successful submission of final clinical protocol and supporting CMC information to FDA to initiate Phase 3 VERSATILE-003 trial in the
PDS Biotechnology Corporation reported its financial results for the second quarter of 2023, highlighting progress in its lead candidate, PDS0101. The company achieved an impressive 12-month overall survival rate of 87% during the VERSATILE-002 trial, paving the way for the initiation of the Phase 3 VERSATILE-003 trial. Despite reporting a net loss of $11.5 million, PDS Biotech maintains a cash position of $60.6 million, sufficient for continued operations and R&D for the next year. Positive data ahead of upcoming trials fuels optimism for future developments in cancer immunotherapy.
Read more →PDSBPDS Biotech to Present Updated Immune Response Data from Combination of PDS0101 and KEYTRUDA (pembrolizumab) in Head and Neck Cancer Patients at ESMO Congress 2023 Data from ongoing VERSATILE-002 trial to highlight HPV16
PDS Biotech has announced the acceptance of an abstract detailing immune response data from its VERSATILE-002 trial, focusing on the combination treatment of PDS0101 and KEYTRUDA in patients with recurrent HPV16-positive head and neck cancer. The trial presents promising results, indicating that PDS0101 can elicit robust immune responses with minimal toxicity. The findings will be showcased at the ESMO Congress 2023, which may enhance awareness and interest in this treatment approach. With HPV-positive head and neck cancers on the rise, PDS Biotech aims to address this unmet medical need through its innovative therapies.
Read more →PDSB▲ +7.6%on this news
PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023 First clinical study of immunoc
PDS Biotechnology Corporation announced that an abstract detailing interim data from a clinical trial combining its investigational drug PDS0301 with docetaxel for metastatic prostate cancer has been accepted for oral presentation at Cytokines 2023. The trial, led by the National Cancer Institute, is designed to evaluate the safety and immune response of this novel combination in patients. PDS0301 represents a novel approach to immunotherapy, aiming to enhance the effectiveness of standard chemotherapy while potentially providing insights for its application across various solid tumors.
Read more →PDSBPDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune and PDS0301 Composition of matter and use patent for Versamune in combination with PDS0301 allowed in Canada PDS Biotech's prop
PDS Biotech has announced that the Canadian Intellectual Property Office has allowed a patent regarding its Versamune technology in combination with PDS0301 for cancer treatment. This patent expands the company's intellectual property rights and enhances market coverage for its immunotherapy innovations. The combination has shown a potential to improve patient outcomes in cancers associated with HPV, with previous studies indicating significantly better survival rates compared to traditional therapies. The company views this patent as a critical asset for its commercialization efforts in Canada and strategic business growth.
Read more →PDSB▼ -9.9%on this news
Developing Transformational Immunotherapies for Cancer NASDAQ: PDSB June 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United S
PDS Biotechnology Corporation is advancing its cancer immunotherapy candidate PDS0101 into Phase 3 clinical trials targeting recurrent or metastatic HPV-positive head and neck squamous cell carcinoma in 2023. The company reported a cash balance of $65.2 million as of March 31, 2023, providing a runway into Q3 2024 to support the trial initiation. PDS0101 is part of the Versamune platform, designed to enhance anti-tumor immune responses. Despite its promising developments, the company faces challenges, including reliance on further financing and potential variances in actual performance relative to projections.
Read more →PDSB▼ -9.9%on this news
PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA in Head and Neck Cancer 14 patients in the immune checkpoint inhibitor na ve arm of VERS
PDS Biotechnology has announced that it achieved the efficacy threshold in Stage 2 of the VERSATILE-002 clinical trial for PDS0101 in combination with KEYTRUDA for treating HPV16-positive head and neck cancer. Fourteen out of the fifty-four enrolled patients reached a confirmed objective response. Recent data presented at the ASCO Annual Meeting indicated a 12-month overall survival rate of 87.1%. The company plans to advance to a Phase 3 study, VERSATILE-003, which will further evaluate the treatment's efficacy and safety.
Read more →PDSBDeveloping Transformational Immunotherapies for Cancer NASDAQ: PDSB May 2023 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United St
PDS Biotechnology Corporation is preparing to enter a Phase 3 registrational trial this year for PDS0101, which targets recurrent or metastatic HPV-positive head and neck squamous cell cancer (HNSCC). The company has reported a cash runway that extends into the third quarter of 2024, providing a foundation for its ongoing clinical trials and operations. Forward-looking statements emphasize the potential for the company to fill significant unmet medical needs in a growing market, though it acknowledges certain financial and operational risks associated with its business model.
Read more →PDSB▼ -7%on this news· ran to +33% by day 3
PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA (pembrolizumab) for Head and Neck Cancer Patients Interim data being presented at ASCO 2023 Annual M
PDS Biotechnology Corporation announced promising interim data from its VERSATILE-002 Phase 2 clinical trial, demonstrating a 12-month survival rate of 87% for patients with HPV16-positive head and neck cancer treated with PDS0101 in combination with KEYTRUDA. The findings indicate that this combination therapy is well tolerated, with only 8% of patients experiencing serious side effects. The data encourages further investigation, and a global confirmatory study named VERSATILE-003 is planned to begin this year. This information will be presented at the upcoming ASCO 2023 Annual Meeting.
Read more →PDSBPDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Na ve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer Company plans to initiate VERSATILE-003 Phase 3 clinical t
PDS Biotech has completed enrollment for the ICI na ve arm of its VERSATILE-002 Phase 2 trial, which focuses on treating HPV16-positive head and neck cancer. The trial combines PDS0101 with KEYTRUDA and has shown preliminary promising data, including a 41% objective response rate. Moving forward, PDS Biotech plans to initiate a Phase 3 trial by late 2023. Updated data from the VERSATILE-002 trial will be presented at the upcoming ASCO 2023 meeting.
Read more →PDSBPrecision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | May 2023 2 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E
PDS Biotechnology Corporation provided an investor presentation discussing its forward-looking statements, including the anticipated entry of PDS0101 into a Phase 3 registrational trial for recurrent or metastatic HPV-positive head and neck cancer in 2023. The company emphasized its strong cash position, with $65.2 million available to sustain its operations into the third quarter of 2024. However, it also acknowledged various risks related to financing, clinical trials, and intellectual property protection that could affect its future performance and business strategy.
Read more →PDSB▲ +7.4%on this newsshared move
PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results Updated data from VERSATILE-002 Phase 2 trial to be presented at ASCO 2023 Company to host conference call and webcast today
PDS Biotech has provided a business update along with its financial results for the first quarter of 2023. The company is advancing towards the initiation of a Phase 3 clinical trial for its immunotherapy product PDS0101, with updated data from the ongoing Phase 2 trial expected at ASCO 2023. However, PDS Biotech reported a net loss for the quarter and increasing operational costs. Nevertheless, they maintain a sufficient cash reserve to support operations through mid-2024.
Read more →PDSBPrecision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | April 2023 2 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21
PDS Biotechnology Corporation presented forward-looking statements regarding its development in immunotherapy, specifically targeting HPV-related head and neck cancer through its PDS0101 candidate. The company is preparing to enter a Phase 3 registrational trial in 2023 and has a cash runway extending to Q3 2024. Backed by significant partnerships and a solid management team, PDS is positioned to explore new avenues in cancer immunotherapy.
Read more →PDSBPDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA (pembrolizumab) in Head and Neck Cancer Patients Abstract selected
PDS Biotechnology Corporation has announced the presentation of updated data from its VERSATILE-002 study at the upcoming 2023 ASCO Annual Meeting. This study evaluates the efficacy and safety of PDS0101, an HPV-targeted immunotherapy, in combination with Merck's KEYTRUDA for patients with recurrent or metastatic HPV-positive head and neck cancer. The abstract has been selected for a featured poster presentation, highlighting its significance within the discussion on head and neck cancer. Preliminary results indicate potential benefits regarding tumor shrinkage and overall survival rates in patients receiving the combination therapy.
Read more →PDSBPDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program
PDS Biotech has successfully received $1.4 million by selling its net operating loss tax benefits through New Jersey's Economic Development Program. This funding is expected to support the transition of their lead therapeutic candidate, PDS0101, into a registrational trial targeting HPV16-positive metastatic or recurrent head and neck cancer. The New Jersey program allows qualifying biotech firms to convert tax losses into cash, aiding in financing operational and developmental expenses. However, PDS Biotech acknowledges its dependence on additional financing for future growth and development initiatives.
Read more →PDSBInterleukin-12 (IL-12) KOL Roundtable NASDAQ: PDSB |
The article discusses a KOL (Key Opinion Leader) roundtable hosted by PDS Biotechnology Corporation focusing on Interleukin-12 (IL-12) therapies. Experts presented the historical context of IL-12, detailing previous challenges such as toxicity and limited efficacy in trials. They highlighted NHS-IL12 (PDS0301) as a promising avenue, benefiting from targeted delivery to tumors, which could enhance efficacy and patient tolerability. The discussions underscore ongoing concerns about IL-12's use, particularly its historical safety issues and current clinical development strategies.
Read more →PDSBPDS Biotech to Host Interleukin 12 (IL-12) Immunocytokine-Focused KOL Roundtable on
PDS Biotechnology Corporation announced it will host a Key Opinion Leader Roundtable on April 21, 2023, focusing on the potential of the IL-12 immunocytokine in oncology and the promising clinical results of their investigational product PDS0301. This event aims to engage analysts, investors, and the scientific community, showcasing advancements in cancer immunotherapy. The roundtable will be moderated by PDS Biotech's Chief Medical Officer, Dr. Lauren Wood, and include presentations from notable cancer researchers. Attendance and webcast availability indicate PDS Biotech's commitment to transparency and collaboration in advancing cancer treatment.
Read more →PDSB▲ +5.4%on this newsshared move
Precision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | April 2023 2 This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Secu
PDS Biotechnology Corporation provided an investor presentation highlighting its forward-looking statements and strategic plans focusing on immunotherapy. The presentation discussed the promising clinical efficacy of PDS0101, particularly in HPV16-positive cancers, including data from ongoing Phase 3 trials. The company emphasized its partnerships and robust financial position, aiming for registrational trials and strengthening its research and development efforts.
Read more →PDSBPDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA in Head and Neck Cancer in 2023 Company has completed Phase 3 manufacturing of PDS0101 for randomized, controlled, regi
PDS Biotechnology Corporation announced its plan to initiate a Phase 3 clinical trial named VERSATILE-003, evaluating its immunotherapy PDS0101 in combination with KEYTRUDA for patients with recurrent/metastatic HPV16-positive head and neck cancer. The trial, set to begin in Q4 2023, follows successful Phase 2 results and FDA guidance. The company has completed the necessary manufacturing processes and plans to amend its IND application to the FDA. PDS Biotech aims to address the considerable treatment gaps in treating this patient population.
Read more →PDSBPDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results Successful meeting with FDA to discuss registrational pathway for triple combination of PDS0101, PDS0301, and a commerc
PDS Biotech reported its fourth-quarter and full-year 2022 financial results, highlighting significant progress in clinical developments, especially with their lead candidate PDS0101. The company received FDA guidance regarding the regulatory pathway for their Phase 2 trials, including a triple combination therapy and has partnered with Merck KGaA for advancing PDS0301. However, financial results showed a notable increase in net loss primarily due to increased expenditures in research and development, as well as operational costs.
Read more →PDSBPrecision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | March 2023 2 Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E
PDS Biotechnology Corporation is progressing its immunotherapy pipeline as it prepares for a Phase 3 registrational trial for its candidate PDS0101, aimed at treating HPV16-positive cancers. The company announced a solid cash runway anticipated to last until Q2 2024, leveraging critical partnerships with Merck and major cancer research institutes. However, PDS is aware of the risks surrounding its dependence on future monetary support and the uncertainties linked to upcoming clinical trials.
Read more →PDSBPDS Biotech Announces the Publication of PDS0301 Study Linking Induced Changes in Immune Responses with Clinical Outcomes in International Immunopharmacology Journal National Cancer Institute (NCI)-led research of PDS030
PDS Biotech has announced the publication of a study led by the National Cancer Institute that highlights the effects of PDS0301, an investigational IL-12 fusion protein, on immune responses and clinical outcomes in cancer patients. The study's findings indicate that higher doses of PDS0301 are associated with improved immune cell activation and better clinical results. Researchers evaluated patient responses according to varying doses and treatment schedules during a Phase 1 clinical trial, emphasizing the therapeutic potential of PDS0301 in addressing advanced cancers. The research was published in the International Immunopharmacology journal, further supporting the efficacy of the novel treatment.
Read more →PDSBPDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor Received guidance on registrational path for combination in recurrent/metastatic,
PDS Biotech announced a successful Type B meeting with the FDA regarding a triple combination therapy involving PDS0101, PDS0301, and a commercial immune checkpoint inhibitor. This therapy targets recurrent/metastatic HPV-positive head and neck cancer, demonstrating a promising median overall survival of 21 months in clinical trials, significantly higher than historical survival rates. The FDA provided guidance on the study design for a potential registrational trial, simplifying the regulatory pathway for the combination treatment. PDS0101 and PDS0301 are designed to significantly enhance the response to treatment in patients who have failed prior therapies.
Read more →PDSBPDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune Infectimune (R-DOTAP) nanoparticles significantly enhance cytokine-inducing, CD4 T cell
PDS Biotech announced a significant publication detailing the effectiveness of its Infectimune (R-DOTAP) nanoparticles in inducing CD4 T cell responses, outperforming leading vaccine adjuvants in preclinical trials. The research, carried out at the University of Rochester, emphasizes the potential of Infectimune to generate strong immune responses against influenza and potentially other viruses. The findings were reported in the journal Viruses, showcasing that the technology could lead to more effective vaccines in the future. This advancement aligns with PDS Biotech's goal of addressing immune challenges, particularly in vulnerable populations such as the elderly.
Read more →PDSBPDS Biotech Announces Publication of Preclinical Infectimune Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses Infectimune induced neutralizing antibody an
PDS Biotechnology Corporation has published promising preclinical studies on their novel vaccine platform, Infectimune, in the journal Viruses. The studies show that Infectimune generates a robust immune response capable of protecting against lethal challenges from SARS-CoV-2 and influenza viruses. The platform has demonstrated the potential for developing next-generation universal vaccines by inducing strong antibody and T cell responses. This research underscores the potential of Infectimune to provide long-lasting protection against infectious diseases.
Read more →PDSBPDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies Congress Abstract, titled "HPV16-specific CD4 and CD8 T cell activation and functionality in patients receiving combination P
PDS Biotechnology Corporation has announced that its abstract titled "HPV16-specific CD4 and CD8 T cell activation and functionality in patients receiving combination PDS0101 immunotherapy" has been accepted for presentation at the ESMO Targeted Anticancer Therapies Congress in Paris. This research presents data from the VERSATILE-002 Phase 2 study, exploring the effects of the PDS0101 immunotherapy in combination with KEYTRUDA on T cell activation in patients with HPV16-positive head and neck cancer. The acceptance of this abstract highlights the potential of PDS0101 in advancing cancer treatment through targeted immunotherapy.
Read more →PDSBPrecision Designed Science For Immunotherapy Oncology Platforms and Clinical Data Summary NASDAQ: PDSB | January 2023 2 Certain information in this presentation may include forward-looking statements (including within th
PDS Biotechnology Corporation is advancing its proprietary immunotherapy platforms with a focus on cancer treatment. The company highlights recent achievements including the FDA Fast Track designation for PDS0101. Clinical data showcases promising response rates in treating HPV-positive cancers, indicating potential effectiveness. However, challenges remain, particularly regarding funding and the inherent uncertainties of clinical trial processes.
Read more →PDSB▼ -19.5%on this news
PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany PDS Biotech bolsters immuno-oncology portfolio with a clinical-stage product
PDS Biotech has entered into an exclusive global license agreement with Merck KGaA for the investigational IL-12 tumor-targeted cytokine, M9241. The acquisition of M9241, which enhances T cell potency, will bolster PDS's immunotherapy pipeline along with its proprietary Versamune platform. PDS Biotech will take on responsibility for the development, commercialization, and manufacturing of M9241, following an upfront payment and milestone terms benefitting Merck KGaA. The partnership aims to advance innovative cancer treatment options, particularly for patients with challenging cases.
Read more →PDSB▲ +23.8%on this news· ran to +40% by day 1shared move
PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 months Median OS of 21 months in 2
PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 months Median OS of 21 months in 29 checkpoint inhibitor (CPI) refractory HPV16-positive can
Read more →PDSBPDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer VERSATILE-002 Phase 2 study investigating PDS0101 in combin
PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and VERSATILE-002 Phase 2 study investigating PDS0101 in combination with Merck's KEYTRUDA (pembrolizumab) in both checkpoint inhibito
Read more →PDSBPrecision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | December 2022 2 Certain information in this presentation may include forward-looking statements (including within the meaning of Section 2
Precision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | December 2022 2 Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934,
Read more →PDSBPDS Biotech Executives to Present an Overview of Oncology and Infectious Disease Programs at the World Vaccine & Immunotherapy Congress Chief Medical Officer, Dr. Lauren V. Wood, to present on the development of targeted
PDS Biotech Executives to Present an Overview of Oncology and Infectious Disease Programs at the World Vaccine & Immunotherapy Congress Chief Medical Officer, Dr. Lauren V. Wood, to present on the development of targeted immunotherapies for solid tumors based on the Versamune D
Read more →PDSB▲ +26.1%on this news· ran to +67% by day 3
PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update Announced preliminary PDS0101 efficacy and safety data for Phase 2 clinical studies led by The University of Texas MD Anderson Cancer
PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update FLORHAM PARK, N.J., November 14, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunot
Read more →PDSB▲ +6.6%on this news
PDS Biotech Announces Presentation of Preliminary PDS0101 Efficacy, Safety, and Immunology Data at Society for Immunotherapy of Cancer (SITC 2022) Patients with high-risk, locally advanced cervical cancer on IMMUNOCERV d
PDS Biotech Announces Presentation of Preliminary PDS0101 Efficacy, Safety, and Immunology Data at Society for Immunotherapy of Cancer (SITC 2022) Patients with high-risk, locally advanced cervical cancer on IMMUNOCERV demonstrated increased tumor-infiltrating polyfunctional CD
Read more →PDSBPDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable Jared Weiss, MD, Lead Investigator for the VERSATILE-002 clinical trial combining PDS0101 and KEYTRUDA , presents interim data from the study Combi
PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable Jared Weiss, MD, Lead Investigator for the VERSATILE-002 clinical trial combining PDS0101 and KEYTRUDA , presents interim data from the study Combination shows potential to achieve oncologists' goals of im
Read more →PDSB▼ -5.2%on this newsshared move
Head and Neck Cancer KOL Roundtable NASDAQ: PDSB |
Head and Neck Cancer KOL Roundtable NASDAQ: PDSB | October 26, 2022 Forward Looking Statements Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as a
Read more →PDSBPDS Biotech Announces Abstract Demonstrating Versatility of the Versamune Platform in Oncology Accepted for Presentation at AACR Special Conference on Tumor Immunology and Immunotherapy Abstract highlights foundational r
PDS Biotech Announces Abstract Demonstrating Versatility of the Versamune Platform in Oncology Accepted for Presentation at AACR Special Conference on Tumor Immunology and Immunotherapy Abstract highlights foundational research in the development of PDS0102 and PDS0103 Florham
Read more →PDSBPDS Biotech to Host Head and Neck Cancer KOL Roundtable on
PDS Biotech to Host Head and Neck Cancer KOL Roundtable on October 26, 2022 Florham Park, NJ, October 12, 2022 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infecti
Read more →PDSB▲ +16.4%on this newsshared move
PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers 66% of HPV 16-positive checkpoint inhibitor refractory patients are alive at median follow u
PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive 66% of HPV 16-positive checkpoint inhibitor refractory patients are alive at median follow up of 16 months Florham Park, NJ, October 11, 2022 - PDS Biotechnol
Read more →PDSBPDS Biotech Announces Abstracts Involving Research of PDS0101 Accepted for Presentation at SITC 2022 Abstracts highlight data from Phase 2 clinical trials - PDS0101-CRT combination study in cervical cancer and PDS0101-ba
PDS Biotech Announces Abstracts Involving Research of PDS0101 Accepted for Presentation at SITC 2022 Abstracts highlight data from Phase 2 clinical trials - PDS0101-CRT combination study in cervical cancer and PDS0101-based triple combination study in HPV16-expressing cancers
Read more →PDSB▲ +10.4%on this news· ran to +25% by day 1shared move
PDS BIOTECH ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH THE FDA AND PREPARATION FOR THE REGISTRATIONAL TRIAL OF PDS0101 IN COMBINATION WITH KEYTRUDA Florham Park, NJ
PDS BIOTECH ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH THE FDA AND PREPARATION FOR THE REGISTRATIONAL TRIAL OF PDS0101 IN COMBINATION Florham Park, NJ, October 3, 2022 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growi
Read more →PDSBPDS Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers Ongoing program to focus on checkpoint inhibitor ref
PDS Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers Ongoing program to focus on checkpoint inhibitor refractory patients following data presented at ASCO 2022 dem
Read more →PDSBPDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance Initial tranche of $25 million provides funding in preparation for registrational trial for lead candidate PDS0101 Conference call s
PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance FLORHAM PARK, N.J., August 24, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targ
Read more →PDSB▲ +6%on this news
Precision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | August 2022 2 Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E
Precision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | August 2022 2 Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as
Read more →PDSBPDS Biotech Reports Second Quarter 2022 Financial Results and Provides Business Update Announced results from two of the ongoing Phase 2 clinical trials of PDS0101 in multiple, difficult-to-treat HPV16-related cancers pr
PDS Biotech Reports Second Quarter 2022 Financial Results and Provides Business Update FLORHAM PARK, N.J., Aug. 8, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immu
Read more →PDSB▲ +10.8%on this newsshared move
PDS Biotech Independent Data Monitoring Committee Recommends VERSATILE-002 Trial Continuation without Modifications Safety evaluation of 43 patients with no grade 3 or higher treatment-related adverse events
PDS Biotech Independent Data Monitoring Committee Recommends VERSATILE-002 Trial Continuation without Modifications Safety evaluation of 43 patients with no grade 3 or higher treatment-related adverse events FLORHAM PARK, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnolog
Read more →PDSBPDS Biotechnology Announces Presentation of Universal Flu Vaccine Preclinical Data at the 41st American Society of Virology Meeting PDS0202 neutralized multiple strains of influenza and provided protection against infect
PDS Biotechnology Announces Presentation of Universal Flu Vaccine Preclinical Data at the 41st American Society of Virology PDS0202 neutralized multiple strains of influenza and provided protection against infection in preclinical studies FLORHAM PARK, N.J., July 14, 2022 (GLOB
Read more →PDSB▼ -5.1%on this news
Precision Designed Science For Immunotherapy Post-ASCO Presentation NASDAQ: PDSB |
Precision Designed Science For Immunotherapy Post-ASCO Presentation NASDAQ: PDSB | June 7, 2022 2 Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, a
Read more →PDSB▼ -5.1%on this news
Precision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | June 2022 2 Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E o
Precision Designed Science For Immunotherapy INVESTOR PRESENTATION NASDAQ: PDSB | June 2 Certain information in this presentation may include forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended
Read more →PDSB▲ +13.7%on this newsshared move
PDS Biotechnology Granted FDA Fast Track Designation for Lead Candidate PDS0101 PDS Biotech has been granted Fast Track designation for PDS0101 in combination with KEYTRUDA (pembrolizumab) for the treatment of recurrent
PDS Biotechnology Granted FDA Fast Track Designation for Lead Candidate PDS0101 PDS Biotech has been granted Fast Track designation for PDS0101 in combination with KEYTRUDA (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer FLORHAM
Read more →PDSB▼ -27.1%on this newsshared move
PDS Biotech Announces Expansion of its VERSATILE-002 Clinical Trial into Europe Promising preliminary clinical results validates epansion of study initially into the united kingdom
PDS Biotech Announces Expansion of its VERSATILE-002 Clinical Trial into Europe Promising preliminary clinical results validates epansion of study initially into the united kingdom FLORHAM PARK, N.J., May 31, 2022 -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stag
Read more →PDSBPDS Biotech Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer at ASCO 2022 Preliminary data from first 19 patients treated with P
PDS Biotech Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or Metastatic Head and Neck Cancer at ASCO 2022 Preliminary data from first 19 patients treated with PDS0101 in combination with KEYTRUDA (pembrolizumab) demon
Read more →PDSBPDS Biotech Announces Presentation of Data from NCI-Led Triple Combination Phase 2 Clinical Trial in Advanced, Refractory HPV-Positive Cancers at ASCO 2022 77% of checkpoint inhibitor (CPI) refractory patients alive at m
PDS Biotech Announces Presentation of Data from NCI-Led Triple Combination Phase 2 Clinical Trial in Advanced, Refractory HPV-Positive Cancers at ASCO 2022 FLORHAM PARK, N.J., May 26, 2022 -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company d
Read more →PDSB▼ -15.9%on this news
PDS Biotech Provides Business Update and Reports First Quarter 2022 Financial Results Company to host conference call and webcast today
PDS Biotech Provides Business Update and Reports First Quarter 2022 Financial Results Company to host conference call and webcast today, May 11, 2022, at 8:00 AM EDT FLORHAM PARK, N.J., May 11, 2022 -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy
Read more →PDSBConfidential PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting Preliminary efficacy and safety update on PDS0101 in combination with KEYTRUDA (
PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual Meeting FLORHAM PARK, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing
Read more →PDSBPDS Biotech Receives $1.2 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program
PDS Biotech Receives $1.2 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program FLORHAM PARK, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company dev
Read more →PDSBPDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2021 Financial Results Company to host conference call and webcast today
PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2021 Financial Results Company to host conference call and webcast today, March 31, 2022, at 8:00 AM EDT FLORHAM PARK, N.J., March 31, 2022 -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-
Read more →PDSB▲ +7.5%on this news· ran to +31% by day 3
PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers NCI achieves the enrollment objective o
PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers NCI achieves the enrollment objective of thirty patients in the checkpoint inhibitor refractory a
Read more →PDSB▲ +5.4%on this news
PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium Preliminary safety data has shown that PDS0101 in combin
PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA (pembrolizumab) at the 2022 Multidisciplinary Head and Neck Cancers Symposium Preliminary safety data has shown that PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembroliz
Read more →PDSBPDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-metastatic- HPV-Associated Head and Neck Cancer The study evaluates PDS0101 with and without KEYTRUDA prior to surgery for HPV-ass
PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-metastatic- HPV-Associated Head and Neck Cancer The study evaluates PDS0101 with and without KEYTRUDA prior to surgery for HPV-associated oropharyngeal cancer FLORHAM PARK, N.J., Feb. 15,
Read more →PDSBPDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA (pembrolizumab) in Advanced Head and Neck Cancer Achievement of initial efficacy milestone all
PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEYTRUDA (pembrolizumab) in Advanced Head and Neck Cancer Achievement of initial efficacy milestone allows full enrollment of checkpoint inhibitor na ve cohort
Read more →PDSB▼ -8.1%on this news
PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine PDS0202 (Infectimune + COBRA Influenza Antigens) neutralized multiple strains of the flu and provided effective protection against infection
PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine PDS0202 (Infectimune + COBRA Influenza Antigens) neutralized multiple strains of the flu and provided effective protection against infection in preclinical studies Florham Park N.J., Jan. 27, 2022 (
Read more →PDSBPDS Biotech Granted Patent for its Novel HPV16 Immunotherapy Extends patent protection of PDS0101 by the United States Patent and Trademark Office Until October 2037 Florham Park N.J.
PDS Biotech Granted Patent for its Novel HPV16 Immunotherapy Extends patent protection of PDS0101 by the United States Patent and Trademark Office Until October 2037 Florham Park N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-st
Read more →PDSBINVESTOR PRESENTATION Frank Bedu-Addo Ph.D. President & CEO January 2022 2 This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strat
INVESTOR PRESENTATION Frank Bedu-Addo Ph.D. President & CEO January 2022 2 This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including but not limited to statements r
Read more →PDSBPDS Biotech Provides Recruitment update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination Institutional Review Board (IRB) approval has been obtained and clinical trial recruitment res
PDS Biotech Provides Recruitment update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination Institutional Review Board (IRB) approval has been obtained and clinical trial recruitment resumes Florham Park, NJ, December 6, 2021 - PDS Biotechnolog
Read more →PDSBPDS Biotech Provides Business Update and Reports Third Quarter 2021 Financial Results
PDS Biotech Provides Business Update and Reports Third Quarter 2021 Financial Results FLORHAM PARK, N.J., November 10, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious
Read more →PDSBPDS Biotech Provides Update on National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination Temporary administrative suspension of recruitment - No safety or efficacy concerns related specifically to
PDS Biotech Provides Update on National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination Temporary administrative suspension of recruitment - No safety or efficacy concerns related specifically to the novel PDS0101-based combination Florham Park, NJ, Oct
Read more →PDSBCORPORATE OVERVIEW Frank Bedu-Addo Ph.D. President & CEO OCTOBER 2021 2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, b
CORPORATE OVERVIEW Frank Bedu-Addo Ph.D. President & CEO OCTOBER 2021 2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including but not
Read more →PDSBPDS Biotech Enrolls First Stage of Checkpoint Inhibitor Na ve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer Florham Park, NJ
PDS Biotech Enrolls First Stage of Checkpoint Inhibitor Na ve Patient Arm of Phase 2 Clinical Trial in Advanced HPV-16 Positive Head and Neck Cancer Florham Park, NJ, October 4, 2021 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developin
Read more →PDSBPDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA in Advanced Head and Neck Cancer No dose limiting toxicities observed in init
PDS Biotech Achieves Safety Requirement Milestone For the First 12 Patients in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA in Advanced Head and Neck Cancer No dose limiting toxicities observed in initial group of 12 patients Florham Park, NJ, September 20,
Read more →PDSBPDS Biotech Completes Enrollment of Lead-In Safety Cohort in VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA in Recurrent or Metastatic Head and Neck Cancer Florham Park, NJ
PDS Biotech Completes Enrollment of Lead-In Safety Cohort in VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA in Recurrent or Metastatic Head and Neck Cancer Florham Park, NJ, September 9, 2021 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunoth
Read more →PDSBPDS Biotech Provides Business Update and Reports Second Quarter 2021 Financial Results
PDS Biotech Provides Business Update and Reports Second Quarter 2021 Financial Results FLORHAM PARK, N.J., August 12, 2021 (GLOBE NEWSWIRE) --PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Compa
Read more →PDSBCORPORATE OVERVIEW Frank Bedu-Addo Ph.D. President & CEO AUGUST 2021 * Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, bu
CORPORATE OVERVIEW Frank Bedu-Addo Ph.D. President & CEO AUGUST 2021 * Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including but not
Read more →PDSBPDS Biotech Announces Proposed Offering of Common Stock Florham Park, NJ
PDS Biotech Announces Proposed Offering of Common Stock Florham Park, NJ, June 14, 2021 - PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary V
Read more →PDSBCORPORATE OVERVIEW Frank Bedu-Addo Ph.D. President & CEO JUNE 2021 2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, busi
CORPORATE OVERVIEW Frank Bedu-Addo Ph.D. President & CEO JUNE 2021 2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including but not li
Read more →PDSBPDS Biotechnology Expands VERSATILE-002 study of PDS0101 and KEYTRUDA in Advanced Head and Neck Cancer to Include Patients Who Have Failed Prior Treatment with Checkpoint Inhibitors Florham Park, NJ
PDS Biotechnology Expands VERSATILE-002 study of PDS0101 and KEYTRUDA in Advanced Head and Neck Cancer to Include Patients Who Have Failed Prior Treatment with Checkpoint Inhibitors Florham Park, NJ, June 3, 2021 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
Read more →PDSBCORPORATE OVERVIEW Frank Bedu-Addo Ph.D. President & CEO MAY 2021 2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, busin
CORPORATE OVERVIEW Frank Bedu-Addo Ph.D. President & CEO MAY 2021 2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including but not lim
Read more →PDSBPDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting Objective responses (tumor reduction) observed in 83% (5 of 6) of HPV16-positive relapsed
PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting Objective responses (tumor reduction) observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor na ve patients and 63%
Read more →PDSBPDS Biotech Receives $4.5M After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program Florham Park, NJ
PDS Biotech Receives $4.5M After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program Florham Park, NJ, May 17, 2021 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapie
Read more →PDSBPDS Biotech Provides Business Update and Reports First Quarter 2021 Financial Results
PDS Biotech Provides Business Update and Reports First Quarter 2021 Financial Results FLORHAM PARK, N.J., May 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disea
Read more →PDSBPDS Biotech Announces Oral Presentation of PDS0101 Data by the National Cancer Institute at 2021 American Society of Clinical Oncology Annual Meeting Florham Park, NJ
PDS Biotech Announces Oral Presentation of PDS0101 Data by the National Cancer Institute at 2021 American Society of Clinical Oncology Annual Meeting Florham Park, NJ, April 29, 2021 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developin
Read more →PDSBPDS Biotech Reports Financial Results for the Year Ended
PDS Biotech Reports Financial Results for the Year Ended December 31, 2020 and Provides Business Update Florham Park, NJ, March 18, 2021 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disea
Read more →PDSBPDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of a Versamune
PDS Biotech Announces that its COVID-19 Vaccine Consortium Received a Commitment from The Ministry of Science, Technology and Innovation of Brazil (MCTI) to fund Clinical Development and Commercialization of a Versamune -Based COVID-19 Vaccine with an Award of up to Approx. US$6
Read more →PDSBPDS Biotech and Farmacore Announce Blanver to Join Consortium to Commercialize Novel Versamune -Based T-Cell Inducing COVID-19 Vaccine Brazilian-based Blanver brings depth of expertise in development and commercializatio
PDS Biotech and Farmacore Announce Blanver to Join Consortium to Commercialize Novel Versamune -Based T-Cell Inducing COVID-19 Vaccine Brazilian-based Blanver brings depth of expertise in development and commercialization of innovative pharmaceuticals across Latin America Florh
Read more →PDSBPDS Biotech Announces Preliminary Efficacy Achievement in Phase 2 Combination Trial of PDS0101 Led by the National Cancer Institute Full enrollment triggered by observation of 3 objective responses in continued evaluatio
PDS Biotech Announces Preliminary Efficacy Achievement in Phase 2 Combination Trial of PDS0101 Led by the National Cancer Institute Full enrollment triggered by observation of 3 objective responses in continued evaluation of the initial group of 8 patients Florham Park, NJ, Fe
Read more →PDSBPDS Biotech Releases White Paper Detailing the Potential of the Versamune Platform in Overcoming a Major Limitation of Immuno-Oncology Promotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment Florha
PDS Biotech Releases White Paper Detailing the Potential of the Versamune Platform in Overcoming a Major Limitation of Immuno-Oncology Promotes in-vivo tumor-attacking killer T-cells to facilitate cancer treatment Florham Park, NJ, January 14, 2021 - PDS Biotechnology Corporat
Read more →PDSBCORPORATE OVERVIEW Frank Bedu-Addo Ph.D. President & CEO JANUARY 2021 2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, b
CORPORATE OVERVIEW Frank Bedu-Addo Ph.D. President & CEO JANUARY 2021 2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including but not
Read more →PDSBPDS Biotech Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamune -based COVID-19 Vaccine Versamune T-cell activating platform demonstrates breadth of anti-SARS-CoV-2 immune r
PDS Biotech Announces Mount Sinai Publication of Studies Showing Superior Induction of Antibodies by Versamune -based COVID-19 Vaccine Versamune T-cell activating platform demonstrates breadth of anti-SARS-CoV-2 immune responses in a COVID-19 vaccine Florham Park, NJ, December
Read more →PDSBPDS Biotechnology Appoints Seth Van Voorhees as Chief Financial Officer Florham Park, NJ
PDS Biotechnology Appoints Seth Van Voorhees as Chief Financial Officer Florham Park, NJ, December 9, 2020 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Compan
Read more →PDSBCORPORATE OVERVIEW Frank Bedu-Addo Ph.D. President & CEO NOVEMBER 2020 2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses,
CORPORATE OVERVIEW Frank Bedu-Addo Ph.D. President & CEO NOVEMBER 2020 2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including but no
Read more →PDSBPDS Biotechnology Reports Financial Results for the Third Quarter 2020 and Provides Business Update Florham Park, NJ
PDS Biotechnology Reports Financial Results for the Third Quarter 2020 and Provides Business Update Florham Park, NJ, November 11, 2020 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious diseas
Read more →PDSBPDS Biotechnology Appoints Renowned Oncologist Otis Brawley, M.D. to its Board of Directors Florham Park, NJ
PDS Biotechnology Appoints Renowned Oncologist Otis Brawley, M.D. to its Board of Directors Florham Park, NJ, November 5, 2020 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccine
Read more →PDSBCORPORATE PRESENTATION Frank Bedu-Addo Ph.D. President & CEO SEPTEMBER 2020 2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its busines
CORPORATE PRESENTATION Frank Bedu-Addo Ph.D. President & CEO SEPTEMBER 2020 2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including b
Read more →PDSBPDS Biotechnology Reports Financial Results for the Second Quarter 2020 and Provides Business Update Florham Park, NJ
PDS Biotechnology Reports Financial Results for the Second Quarter 2020 and Provides Business Update Florham Park, NJ, August 13, 2020 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease
Read more →PDSBPDS Biotechnology Corporation Announces Proposed Public Offering of Common Stock Florham Park, NJ
PDS Biotechnology Corporation Announces Proposed Public Offering of Common Stock Florham Park, NJ, August 10, 2020 - PDS Biotechnology Corporation ("PDS Biotech" or the "Company") (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infec
Read more →PDSBPDS Biotech Announces Preclinical Data for PDS0203, a T-Cell Activating Recombinant Protein Vaccine Against COVID-19 Versamune-CoV-2 (PDS0203) generated high levels of robust, long-lasting CD8 (killer) T-cell responses a
PDS Biotech Announces Preclinical Data for PDS0203, a T-Cell Activating Recombinant Protein Vaccine Against COVID-19 Versamune-CoV-2 (PDS0203) generated high levels of robust, long-lasting CD8 (killer) T-cell responses and potent neutralizing antibody responses within 14 days of
Read more →PDSBPDS Biotech Collaborator Granted NIAID Award to Accelerate Development of Versamune -Based Universal Influenza Vaccine PDS Biotech ramps up third infectious disease vaccine program, PDS0202 for influenza, following PDS02
PDS Biotech Collaborator Granted NIAID Award to Accelerate Development of Versamune -Based Universal Influenza Vaccine PDS Biotech ramps up third infectious disease vaccine program, PDS0202 for influenza, following PDS0201 for tuberculosis and PDS0203 for COVID-19 Florham Park,
Read more →PDSBPDS Biotech Announces Publication of Preclinical Results of PDS0101 Combination by the National Cancer Institute in the Journal for ImmunoTherapy of Cancer NCI-led Phase 2 clinical trial of this reported combination was
PDS Biotech Announces Publication of Preclinical Results of PDS0101 Combination by the National Cancer Institute in the Journal for ImmunoTherapy of Cancer NCI-led Phase 2 clinical trial of this reported combination was initiated in June 2020 Florham Park, NJ, June 22, 2020 -
Read more →PDSBPDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 Led by the National Cancer Institute Florham Park, NJ
PDS Biotech Announces Initiation of Phase 2 Trial of PDS0101 Led by the National Cancer Institute Florham Park, NJ, June 15, 2020 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vacci
Read more →PDSBCORPORATE PRESENTATION Frank Bedu-Addo Ph.D. President & CEO JUNE 2020 2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses,
CORPORATE PRESENTATION Frank Bedu-Addo Ph.D. President & CEO JUNE 2020 2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including but no
Read more →PDSBPDS Biotech Announces Clinical Trial of Its Lead Immunotherapy Product, PDS0101, in Combination with Chemoradiotherapy in Advanced Cervical Cancer Florham Park, NJ
PDS Biotech Announces Clinical Trial of Its Lead Immunotherapy Product, PDS0101, in Combination with Chemoradiotherapy in Advanced Cervical Cancer Florham Park, NJ, June 4, 2020 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing nov
Read more →PDSBPDS Biotechnology Announces Publication at American Society of Clinical Oncology (ASCO) 2020 Florham Park , NJ
PDS Biotechnology Announces Publication at American Society of Clinical Oncology (ASCO) 2020 Florham Park, NJ, May 13, 2020 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines b
Read more →PDSBPDS Biotechnology Reports Financial Results for the First Quarter 2020 and Provides Business Update Florham Park, NJ
PDS Biotechnology Reports Financial Results for the First Quarter 2020 and Provides Business Update Florham Park, NJ, May 13, 2020 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vac
Read more →PDSBPDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza; Delay of PDS0101 VERSATILE-002 trial Expanded infectious disease program to address current and potential pandemics bui
PDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza; Delay of PDS0101 VERSATILE-002 trial Expanded infectious disease program to address current and potential pandemics builds on existing tuberculosis collaboration Initiation of P
Read more →PDSBPDS Biotechnology Appoints Dr. Ilian Iliev to Board of Directors Princeton, NJ
PDS Biotechnology Appoints Dr. Ilian Iliev to Board of Directors Princeton, NJ, April 9, 2020 - PDS Biotechnology Corporation ("PDS Biotechnology") (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on T-cell activating technology called
Read more →PDSBCORPORATE PRESENTATION Frank Bedu-Addo Ph.D. President & CEO APRIL 2020 2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses,
CORPORATE PRESENTATION Frank Bedu-Addo Ph.D. President & CEO APRIL 2020 2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including but n
Read more →PDSBPDS Biotechnology Reports Full Year 2019 Financial Results and Provides Business Update Princeton, NJ
PDS Biotechnology Reports Full Year 2019 Financial Results and Provides Business Update Princeton, NJ, March 27, 2020 - PDS Biotechnology Corporation ("PDS Biotechnology") (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on T-cell act
Read more →PDSBPDS Biotechnology Announces Resignation of Andrew Saik as CFO Princeton, NJ
PDS Biotechnology Announces Resignation of Andrew Saik as CFO Princeton, NJ, March 23, 2020 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company's proprietary Versamune T-cell activating tech
Read more →PDSBPDS Biotechnology Appoints Kamil Ali-Jackson, Esq. to Board of Directors Princeton, NJ
PDS Biotechnology Appoints Kamil Ali-Jackson, Esq. to Board of Directors Princeton, NJ, February 24, 2020 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company's proprietary Versamune T-cell a
Read more →PDSBPDS Biotechnology Corporation Announces Pricing of Public Offering of Approximately $12 Million of Shares of Common Stock Princeton, NJ, February 1 1, 2020 - PDS Biotechnology Corporation ("PDS Biotechnology") (Nasdaq: P
PDS Biotechnology Corporation Announces Pricing of Public Offering of Approximately $12 Million of Shares of Common Stock Princeton, NJ, February 11, 2020 - PDS Biotechnology Corporation ("PDS Biotechnology") (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing m
Read more →PDSBCORPORATE PRESENTATION Frank Bedu-Addo Ph.D. President & CEO JANUARY 2020 2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesse
CORPORATE PRESENTATION Frank Bedu-Addo Ph.D. President & CEO JANUARY 2020 2 Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including but
Read more →PDSBPDS Biotechnology Announces Principal Investigator and Independent Data Monitoring Committee for its Phase 2 Clinical Collaboration with Merck Study evaluating PDS0101-KEYTRUDA (pembrolizumab) Combination in First Line T
PDS Biotechnology Announces Principal Investigator and Independent Data Monitoring Committee for its Phase 2 Clinical Collaboration with Merck Study evaluating PDS0101-KEYTRUDA (pembrolizumab) Combination in First Line Treatment of Metastatic Head and Neck Cancer expected to be
Read more →PDSBPDS Biotechnology Announces Resignation of James Loughlin from Board of Directors Princeton, NJ
PDS Biotechnology Announces Resignation of James Loughlin from Board of Directors Princeton, NJ, December 11, 2019 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company's proprietary Versamune
Read more →PDSBPDS Biotechnology to Present at the 12th Annual LD Micro Main Event Princeton, NJ
PDS Biotechnology to Present at the 12th Annual LD Micro Main Event Princeton, NJ, December 3, 2019 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical stage immuno-oncology company with a broad pipeline of novel products based on the company's proprietary Versamune T-ce
Read more →PDSBPDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019 Princeton, NJ
PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019 Princeton, NJ, November 25, 2019 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company's proprietary
Read more →PDSBPDS Biotechnology Reports Third Quarter 2019 Financial Results and Provides Business Update Princeton, NJ
PDS Biotechnology Reports Third Quarter 2019 Financial Results and Provides Business Update Princeton, NJ, November 7, 2019 - PDS Biotechnology Corporation ("PDS Biotechnology") (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on T-ce
Read more →PDSBPDS Biotechnology Accepted for Oral Presentation at the 34th Annual Society for Immunotherapy of Cancer Annual Meeting Dr. Lauren V. Wood, M.D. to present data from the company's phase 1 PDS0101 human trial demonstrating
PDS Biotechnology Accepted for Oral Presentation at the 34th Annual Society for Immunotherapy of Cancer Annual Meeting Dr. Lauren V. Wood, M.D. to present data from the company's phase 1 PDS0101 human trial demonstrating potent antigen-specific CD8+ T-cell responses in-vivo Pri
Read more →PDSBA new generation of multi-functional cancer immunotherapies October 2019Products, Clinical Indications and Scientific Overview Forward-Looking Statements 2 This presentation contains forward-looking statements about PDS
A new generation of multi-functional cancer immunotherapies October 2019Products, Clinical Indications and Scientific Overview Forward-Looking Statements 2 This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, b
Read more →PDSBPDS Biotechnology Completes Manufacturing of Clinical Batches of PDS0101 Clinical batches support upcoming Phase 2 PDS101 combination trials with Merck and National Cancer Institute Princeton, NJ
PDS Biotechnology Completes Manufacturing of Clinical Batches of PDS0101 Clinical batches support upcoming Phase 2 PDS101 combination trials with Merck and National Cancer Institute Princeton, NJ, October 22, 2019 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
Read more →PDSBPDS Biotechnology Corp. Announces Clinical Collaboration with Merck PDS0101- KEYTRUDA (pembrolizumab) Combination to be Evaluated in First Line Treatment of Metastatic Head and Neck Cancer Berkeley Heights, NJ
PDS Biotechnology Corp. Announces Clinical Collaboration with Merck PDS0101- KEYTRUDA (pembrolizumab) Combination to be Evaluated in First Line Treatment of Metastatic Head Berkeley Heights, NJ, October 3, 2019 / PDS Biotechnology Corporation ("PDS Biotechnology") (Nasdaq: PDSB
Read more →PDSBPDS Biotechnology Prioritizes Development of PDS0101 in Advanced Cancers Following Promising Phase 1 Clinical Outcome Data Data demonstrated regression of lesions in 60% of patients Berkeley Heights, NJ
PDS Biotechnology Prioritizes Development of PDS0101 in Advanced Cancers Following Promising Phase 1 Clinical Outcome Data Data demonstrated regression of lesions in 60% of patients Berkeley Heights, NJ, October 1, 2019 - PDS Biotechnology Corporation ("PDS Biotechnology") (Nas
Read more →PDSBPDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial 60% of evaluable patients demonstrated a clinical response Clinical activity observed at all dose levels Dat
PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial 60% of evaluable patients demonstrated a clinical response Clinical activity observed at all dose levels Data support previously reported in-vivo induction of active
Read more →PDSBPDS Biotechnology Reports Second Quarter 2019 Financial Results And Provides Business Update Berkeley Heights, NJ
PDS Biotechnology Reports Second Quarter 2019 Financial Results And Provides Business Update Berkeley Heights, NJ, August 1, 2019 - PDS Biotechnology Corporation ("PDS Biotechnology") (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of novel m
Read more →PDSBPDS Biotechnology Reports First Quarter 2019 Financial Results and Provides Business Update Berkeley Heights, NJ
PDS Biotechnology Reports First Quarter 2019 Financial Results and Provides Business Update Berkeley Heights, NJ, May 14, 2019 - PDS Biotechnology Corporation ("PDS Biotechnology") (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of novel mult
Read more →PDSBPDS Biotechnology Appoints Stephen Glover to its Board of Directors Berkeley Heights, NJ
PDS Biotechnology Appoints Stephen Glover to its Board of Directors Berkeley Heights, NJ, April 8, 2019 - PDS Biotechnology Corporation (Nasdaq: PDSB) , a clinical-stage immuno-oncology company developing novel multifunctional immunotherapeutic products, today announced that St
Read more →PDSBPDS Biotechnology Completes Merger with Edge Therapeutics Shares of Combined Company to Commence Trading on Nasdaq Capital Market under New Symbol "PDSB" on
PDS Biotechnology Completes Merger with Edge Therapeutics Shares of Combined Company to Commence Trading on Nasdaq Capital Market under New Symbol "PDSB" on March 18, 2019 Princeton, NJ, March 18, 2019 - PDS Biotechnology Corporation ("PDS Biotechnology"), a clinical-stage imm
Read more →PDSBEdge Therapeutics Announces Full Year 2018 Financial Results
Edge Therapeutics Announces Full Year 2018 Financial Results BERKELEY HEIGHTS, N.J., February 21, 2019 - Edge Therapeutics, Inc. (Nasdaq: EDGE) today announced financial results for the full-year ended December 31, 2018. Cash Position: Cash and cash equivalents totaled $34.6
Read more →PDSBEdge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company -Merger would create publicly-traded immuno-oncology biotechnology company developing novel produc
Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company -Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and -Growing product pipeline utili
Read more →PDSBEdge Therapeutics Reports Third Quarter 2018 Financial Results
Edge Therapeutics Reports Third Quarter 2018 Financial Results BERKELEY HEIGHTS, N.J., November 1, 2018 - Edge Therapeutics, Inc. (Nasdaq: EDGE) today announced financial results for the quarter ended September 30, 2018. Third Quarter Financial Results Cash Position: Cash, cas
Read more →PDSBEdge Therapeutics Reports Second Quarter 2018 Financial Results
Edge Therapeutics Reports Second Quarter 2018 Financial Results BERKELEY HEIGHTS, N.J., August 1, 2018 - Edge Therapeutics, Inc. (Nasdaq: EDGE) today announced financial results for the quarter ended June 30, 2018. Second Quarter Financial Results Cash Position: Cash, cash equ
Read more →PDSBEdge Therapeutics Reports First Quarter 2018 Financial Results
Edge Therapeutics Reports First Quarter 2018 Financial Results BERKELEY HEIGHTS, N.J., May 1, 2018 - Edge Therapeutics, Inc. (Nasdaq: EDGE) today announced financial results for the quarter ended March 31, 2018. First Quarter Financial Results Cash Position: Cash, cash equival
Read more →PDSBEdge Therapeutics Announces Review of Strategic Alternatives
Edge Therapeutics Announces Review of Strategic Alternatives BERKELEY HEIGHTS, N.J., Apr. 30, 2018 - Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced that its Board of Directors is conducting a comprehensive review of strategic alternatives focused on maximizing stockholder
Read more →PDSBEdge Therapeutics Provides Update following Interim Analysis of Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage Study Unlikely To Achieve Primary Efficacy Endpoint; DMC Recommends Discontinuation
Edge Therapeutics Provides Update following Interim Analysis of Phase 3 NEWTON 2 Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage Study Unlikely To Achieve Primary Efficacy Endpoint; DMC Recommends Discontinuation of Study No Unexpected Safety Findings Edge To Reduce Cos
Read more →PDSBEdge Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results Interim Analysis from EG-1962 Phase 3 NEWTON 2 Study in Aneurysmal Subarachnoid Hemorrhage Expected by the End of April 2018 Full Top-Line Dat
Edge Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results Interim Analysis from EG-1962 Phase 3 NEWTON 2 Study in Aneurysmal Subarachnoid Hemorrhage Expected by the End of April 2018 Full Top-Line Data from NEWTON 2 Study Expected in Late 2018 BERKELEY HEIG
Read more →PDSBCorporate Presentation February 2018 Disclaimer This presentation and any statements of representatives of Edge related thereto that are not historical in nature (including but not limited to upcoming milestones) contain
Corporate Presentation February 2018 Disclaimer This presentation and any statements of representatives of Edge related thereto that are not historical in nature (including but not limited to upcoming milestones) contain, or may contain, among other things, certain "forward-look
Read more →PDSBCorporate Presentation January 2018 Disclaimer This presentation and any statements of representatives of Edge related thereto that are not historical in nature (including but not limited to upcoming milestones) contain,
Corporate Presentation January 2018 Disclaimer This presentation and any statements of representatives of Edge related thereto that are not historical in nature (including but not limited to upcoming milestones) contain, or may contain, among other things, certain "forward-looki
Read more →PDSBEdge's EG-1962 Phase 3 NEWTON 2 Study Continues as Planned Following Completion of Futility Analysis BERKELEY HEIGHTS, N.J.
Edge's EG-1962 Phase 3 NEWTON 2 Study Continues as Planned Following Completion of Futility Analysis BERKELEY HEIGHTS, N.J., - December 29, 2017 - Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the mana
Read more →PDSBDecember 2017(Nasdaq: EDGE) Disclaimer This presentation and any statements of representatives of Edge related thereto that are not historical in nature (including but not limited to upcoming milestones) contain, or may
December 2017(Nasdaq: EDGE) Disclaimer This presentation and any statements of representatives of Edge related thereto that are not historical in nature (including but not limited to upcoming milestones) contain, or may contain, among other things, certain "forward-looking state
Read more →PDSBEdge Therapeutics Reports Third Quarter 2017 Financial Results
Edge Therapeutics Reports Third Quarter 2017 Financial Results Appoints Pharmaceutical Industry Veteran Andrew Saik as Chief Financial Officer BERKELEY HEIGHTS, N.J., November 1, 2017 - Edge Therapeutics , Inc. (Nasdaq: EDGE), a clinical-stage biotechnology company developing n
Read more →PDSBEdge Therapeutics Appoints Rosemary A. Crane, Pharmaceutical Industry Leader, to its Board of Directors Former Johnson & Johnson and Bristol-Myers Squibb Executive Brings 30 Years of Commercial and Operations Experience
Edge Therapeutics Appoints Rosemary A. Crane, Pharmaceutical Industry Leader, to its Board of Directors Former Johnson & Johnson and Bristol-Myers Squibb Executive Brings 30 Years of Commercial and Operations Experience BERKELEY HEIGHTS, N.J., - September 19, 2017 - Edge Therap
Read more →PDSBEdge Therapeutics Reports Second Quarter 2017 Financial Results and Continued Operational Progress
Edge Therapeutics Reports Second Quarter 2017 Financial Results and Continued Operational Progress BERKELEY HEIGHTS, N.J., August 1, 2017 - Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management
Read more →PDSBEdge Therapeutics Announces Commercial Supply Agreement for EG-1962 with Oakwood Laboratories BERKELEY HEIGHTS, N.J.
Edge Therapeutics Announces Commercial Supply Agreement for EG-1962 with Oakwood Laboratories BERKELEY HEIGHTS, N.J., - July 6, 2017 - Edge Therapeutics, Inc. (Nasdaq:EDGE) today announced that it has entered into a supply agreement and an amended and restated development agreem
Read more →PDSBExhbit 99.1 Edge Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency Removes Requirement for Pediatric Clinical Studies to Support EG-1962 Marketing Authorization Application in E
Edge Therapeutics Receives Pediatric Investigation Plan Waiver from the European Medicines Agency Removes Requirement for Pediatric Clinical Studies to Support EG-1962 Marketing Authorization Application in Europe BERKELEY HEIGHTS, N.J., June 8, 2017 - Edge Therapeutics, Inc. (
Read more →PDSBEdge Therapeutics Reports First Quarter 2017 Financial Results and Continued Operational Progress
Edge Therapeutics Reports First Quarter 2017 Financial Results and Continued Operational Progress BERKELEY HEIGHTS, N.J., May 3, 2017 - Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management of
Read more →PDSBEdge Therapeutics Announces $18 Million Registered Direct Offering of Common Stock Offering Includes 1,800,000 Shares at a Purchase Price of $10.00 per Share
Edge Therapeutics Announces $18 Million Registered Direct Offering of Common Stock Offering Includes 1,800,000 Shares at a Purchase Price of $10.00 per Share BERKELEY HEIGHTS, N.J., April 19, 2017 - Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical-stage biotechnology company
Read more →PDSBEdge Therapeutics Announces First Patient Randomized in Study of Intracisternal Administration of EG-1962 in Adults with Aneurysmal Subarachnoid Hemorrhage
Edge Therapeutics Announces First Patient Randomized in Study of Intracisternal Administration of EG-1962 in Adults with Aneurysmal Subarachnoid Hemorrhage BERKELEY HEIGHTS, N.J. - March 13, 2017 - Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical-stage biotechnology company de
Read more →PDSBEdge Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
Edge Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results BERKELEY HEIGHTS, N.J., March 2, 2017 - Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management of acute, life-threat
Read more →PDSBEdge Therapeutics Reports Third Quarter Financial Results
Edge Therapeutics Reports Third Quarter Financial Results BERKELEY HEIGHTS, N.J., November 1, 2016 - Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies for the management of acute, life-threatening conditions,
Read more →PDSBEdge Therapeutics Appoints Chief Operating Officer and Makes Inducement Grant under NASDAQ Rule 5635(c)(4) Key hire will lead pre-commercial planning for EG-1962 in aneurysmal subarachnoid hemorrhage
Edge Therapeutics Appoints Chief Operating Officer and Makes Inducement Grant under NASDAQ Rule 5635(c)(4) Key hire will lead pre-commercial planning for EG-1962 in aneurysmal subarachnoid hemorrhage BERKELEY HEIGHTS, N.J. - October 17, 2016 - Edge Therapeutics, Inc. (Nasdaq: E
Read more →PDSBEdge Therapeutics Reports Second Quarter Financial Results and Recent Highlights Initiates EG-1962 Phase 3 NEWTON 2 Study for Aneurysmal Subarachnoid Hemorrhage Closes $20 Million Debt Facility with Hercules Capital, Inc
Edge Therapeutics Reports Second Quarter Financial Results and Recent Highlights Initiates EG-1962 Phase 3 NEWTON 2 Study for Aneurysmal Subarachnoid Hemorrhage Closes $20 Million Debt Facility with Hercules Capital, Inc. BERKELEY HEIGHTS, N.J., August 3, 2016 - Edge Therapeut
Read more →PDSBEdge Therapeutics Announces Closing of $20 Million Debt Facility with Hercules Capital, Inc.
Edge Therapeutics Announces Closing of $20 Million Debt Facility with Hercules Capital, Inc. BERKELEY HEIGHTS, N.J., August 2, 2016 - Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical-stage biotechnology company developing novel hospital-based therapies in the management of ac
Read more →PDSBEdge Therapeutics Announces First Patient Treated in Phase 3 NEWTON 2 Study of EG-1962 in Adult Patients with Aneurysmal Subarachnoid Hemorrhage Pivotal, double-blind, placebo-controlled global study will compare EG-1962
Edge Therapeutics Announces First Patient Treated in Phase 3 NEWTON 2 Study of EG-1962 in Adult Patients with Aneurysmal Subarachnoid Hemorrhage BERKELEY HEIGHTS, N.J. - July 29, 2016 - Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical-stage biotechnology company developing nov
Read more →PDSBEdge Therapeutics Receives FDA Fast Track Designation for EG-1962 for the Treatment of Subarachnoid Hemorrhage Initiation of Phase 3 NEWTON 2 Study on Track for Mid-2016
Edge Therapeutics Receives FDA Fast Track Designation for EG-1962 for the Treatment of Subarachnoid Hemorrhage Initiation of Phase 3 NEWTON 2 Study on Track for Mid-2016 BERKELEY HEIGHTS, N.J. - May 13, 2016 - Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical-stage biotechnolo
Read more →PDSBEdge Therapeutics Reports First Quarter 2016 Financial Results Conference Call today at 8:30 am
Edge Therapeutics Reports First Quarter 2016 Financial Results Conference Call today at 8:30 am ET BERKELEY HEIGHTS, N.J. - May 3, 2016 - Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical stage biotechnology company developing novel hospital-based therapies in the management o
Read more →PDSBEdge Therapeutics Reports Fourth Quarter and Full-year 2015 Financial Results Conference Call today at 8:30 am
Edge Therapeutics Reports Fourth Quarter and Full-year 2015 Financial Results Conference Call today at 8:30 am ET BERKELEY HEIGHTS, N.J. - March 8, 2016 - Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical stage biotechnology company developing novel hospital-based therapies in
Read more →PDSBPhase 1/2a Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study Comparing EG-1962 and Nimodipine in Patients with Aneurysmal Subarachnoid Hemorrhage Department
Phase 1/2a Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study Comparing EG-1962 and Nimodipine in Patients with Aneurysmal Subarachnoid Hemorrhage Department of Neurosurgery, University Medical Center Mannheim, Ruprec
Read more →PDSBEdge Therapeutics Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
Edge Therapeutics Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4) BERKELEY HEIGHTS, N.J. - November 20, 2015 - Edge Therapeutics, Inc. (Nasdaq: EDGE) (the "Company"), a clinical stage biotechnology company developing novel hospital-based therapies in the management
Read more →PDSBEdge Therapeutics Reports Third Quarter 2015 Financial Results Successfully Completed Initial Public Offering
Edge Therapeutics Reports Third Quarter 2015 Financial Results Successfully Completed Initial Public BERKELEY HEIGHTS, N.J. - November 6, 2015 - Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical stage biotechnology company developing novel hospital-based therapies in the ma
Read more →PDSBEdge Therapeutics Names W. Bradford Middlekauff as Senior Vice President, General Counsel and Secretary
Edge Therapeutics Names W. Bradford Middlekauff as Senior Vice President, General Counsel and Secretary BERKELEY HEIGHTS, N.J. - November 5, 2015 - Edge Therapeutics, Inc. (Nasdaq: EDGE), a clinical stage biotechnology company developing novel hospital-based therapies in the
Read more →PDSBOctober 2015 Disclaimer This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, i
Disclaimer This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future fin
Read more →PDSBEdge Therapeutics Receives European Commission Orphan Drug Designation for EG-1962 in the Treatment of Patients with Subarachnoid Hemorrhage
Edge Therapeutics Receives European Commission Orphan Drug Designation for EG-1962 in the Treatment of Patients with Subarachnoid Hemorrhage BERKELEY HEIGHTS, N.J. - October 12, 2015 - Edge Therapeutics, Inc. (Nasdaq: EDGE) today announced that the European Commission (EC) has
Read more →PDSBEdge Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option Berkeley Heights, N.J.
Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option Berkeley Heights, N.J. October 6, 2015 - Edge Therapeutics, Inc. (Nasdaq: EDGE) ("Edge") today announced the closing of its initial public offering of 8,412,423 shares of its c
Read more →Competitive Position
How PDSB ranks across every disease it competes inCompetitive Position is a premium feature
See how PDSB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial